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CHAPTER 1: INTRODUCTION
Introduction
A healthy and full-term gestation is critical for the well-being of the mother and neonate.
During pregnancy, there exists a highly dynamic immunological interface between the mother, the
fetus and the human microbiota (the suite of microorganisms inhabiting our bodies) (1). The
previous assumption that mothers have an altered immune response that may be attributable to the
tolerance of the allograft fetus (2-8) is being challenged (1). From the beginning of pregnancy,
successful embryonic implantation requires that the trophoblasts invade into the uterine wall with
a combination of immunologic tolerance and cell growth (1).
A healthy pregnancy further depends on a robust maternal immunologic system that
tolerates commensal microbiota in non-sterile body sites (e.g. the vagina and the rectum) but yet
fights against bacterial invasion into what have historically been presumed sterile sites such as the
placenta and the amniotic cavity (1).

The advent of next-generation sequencing, and the

unprecedented views of human microbiota it has provided, has increasingly led scientists to
question the sterility of previously presumed sterile organs such as the placenta (9-21). However,
the existence of a placental or intra-amniotic microbiota is counter intuitive, as there is a wellestablished causal link between placental and intra-amniotic infection and adverse pregnancy
outcomes such as preterm birth (22-29). Despite much effort and research, it has proven difficult
to prevent unfavorable perinatal outcomes in many circumstances and many questions remain
unanswered. In order to better inform and prepare doctors and nurses, it is important for basic
scientists to research potential factors contributing to these unfavorable perinatal outcomes. The
efficacious characterization of the human perinatal microbiome is an essential scientific milestone
in understanding health and disease in pregnancy (30).
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From the germ theory of disease to the human microbiome project
Since the widespread acceptance of the germ theory of disease in Europe and North
America in the middle to late 1800s (31-34), the presumption that microscopic organisms are
inherently pathologic has persisted. More than 150 years later, in 2008, the Human Microbiome
Project (HMP) was established by the National Institutes of Health to capitalize on two main
contemporary developments: 1) an understanding that the healthy human body is inhabited by a
large and diverse microbiome (i.e. the microbiota plus its genomic contents) containing more
genetic material than the host itself, and 2) advances in DNA sequencing technologies have made
possible the identification and characterization of complex microbial communities inhabiting the
human body that were previously missed using traditional culture techniques (35).
Over the past decade, the microbiome has become an area of intensive research for its
potential role in human health and disease (30, 36-38). In healthy individuals, bacterial profiles of
microbiota have a high degree of inter-individual variation and yet are nonetheless largely body
site-specific (39). Human microbiota are believed to contribute substantially to physiological stasis
and health. For example, it is thought that normal maternal microbiota in the reproductive tract
may play a role in the acceptance of implanting trophoblasts and the embryo at the onset of
pregnancy by inducing immunologic tolerance (1, 40). Nevertheless, compelling evidence also
demonstrates associations between dysbiotic microbiota and various disease states such as obesity
(41-43), insulin resistance and diabetes (44), asthma (45-47), infectious diarrhea (48),
inflammatory bowel diseases (49, 50) and cancer (51-54).
Studying microbiota and microbiomes
When studying the microbiota and microbiome in a specific location and time, clarity of
definitions is important, as microbiota and microbiome are not equivalent. The microbiota are the
living microorganisms inhabiting a particular site or habitat at a given time, while the microbiome
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is the combined genetic material, and thus the functional potential, of the microorganisms making
up the microbiota (55). Dysbiosis refers to loss of diversity and functionality in a specific
microbiome.
Culture is the standard method used to identify live bacteria in clinical samples (56-59).
The viability, phenotype and genotype of a bacterium can be determined upon successful
cultivation (60-66). However, many bacteria that play important roles in human health and disease
are resistant to standard cultivation techniques (59, 62, 64, 67, 68). Therefore, incomplete
representations of microbiota composition may occur with the use of standard cultivation
techniques (69-81).
On the other hand, phylogenetic marker genes (e.g. the bacterial 16S rRNA gene) and
metagenomes have been targets of molecular surveys of bacterial communities (59, 74, 82-98).
Next-Generation Sequencing (NGS) operates independent of culture techniques and can provide
information about a greater diversity of community members than can culture (69, 74, 77, 80, 93,
98). However, these newer technologies have their own biases and risks. For example, polymerase
chain reaction (PCR) primers may preferentially amplify some bacterial taxa over others (99-104),
and certain bacteria that are present at a low abundance may not be captured (61, 105). Moreover,
the amplification of bacterial DNA from clinical samples does not inform us about the viability of
these bacteria (98, 106). An additional concern regarding NGS of low microbial biomass samples,
such as the placenta and bladder, is the amplification and characterization of background DNA
contaminants (107-112).
In other words, cultivation allows for the potential growth and demonstration of live
bacteria potentially residing in low microbial biomass sites, such as the placenta or bladder. In a
complementary fashion, amplified and sequenced microbial DNA, assessed through NGS
technologies can lead to comprehensive characterization of microbiota and microbiomes based on
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even very small concentrations of DNA, provided we simultaneously show that the microbial
signals obtained from clinical samples are different from signals obtained from corresponding
technical controls addressing potential background DNA contamination (111).
The presumed sterility of the placenta and the bladder is being reevaluated
Next-generation sequencing is a very powerful tool that allows sequencing and profiling
of very low biomass microbial communities. This ability has led researchers to investigate the
existence of microbiomes in organs that have been historically considered sterile, including blood
(113), brain (114), lungs (115), the lymphatic system (116), and the uterus (117). The presumed
sterility of the placenta and the bladder is also being reevaluated. Multiple recent studies have
reported the presence of bacteria in the placenta (9-21). In addition, the perception of the urinary
bladder as being sterile is also being revisited, with reports of resident bacteria in the bladder
outside and within pregnancy that may potentially influence perinatal outcomes (118-126). Being
an obstetrician, and given the significant impact of placental infection and urinary tract infection
on pregnancy, I studied the potential existence of microbiota in the placenta and maternal bladder,
determined if placental microbiota factor into pregnancy complications, especially preterm birth,
and evaluated the response of human trophoblasts to co-incubation with bacteria commonly
viewed as pathogenic or commensal within the human reproductive tract.
Infection, preterm birth, and perinatal morbidity and mortality
The historical paradigm in obstetrics has been that the fetus grows and develops in a
“sterile” environment (i.e. the intra-amniotic cavity and amniotic fluid are devoid of
microorganisms) (127-132). Furthermore, a causal link has been established between intraamniotic infection and preterm birth (22-29). Preterm birth is the leading cause of perinatal
morbidity and mortality worldwide. Every year, an estimated 15 million babies are born preterm
accounting for more than 1 in 10 newborns (133-136). Approximately 500,000 preterm neonates

5
are born annually in the United States alone (137-139). Preterm infants are at an increased risk for
chronic respiratory illness (140, 141), blindness (142), intellectual disabilities (143-145), cerebral
palsy (143, 146, 147), and death. The financial burden of prematurity to the United States is
estimated to be $26 billion annually (148). The causal link between intra-amniotic infection and
preterm birth (22-29) highlights the importance of understanding whether microbiota exist in the
placenta of asymptomatic pregnant women who do not exhibit signs or symptoms of infection.
Proponents of the existence of placental microbiota suggest that bacteria could coexist with
trophoblasts in the villous tree within the healthy full-term placenta without triggering
inflammatory manifestations of infection (149).
Birth constitutes a critical transitional stage for the acquisition of neonatal microbiota, and
delivery of the placenta follows the delivery of the baby. The “sterile womb” hypothesis suggests
that the placenta and intra-amniotic environments are sterile and that the human neonate is first
inoculated with colonizing microbes during labor and delivery (130, 150). The mode of delivery,
vaginal or cesarean, has been shown to affect the microbiota of the newborn (151-153). During a
vaginal delivery, the newborn is exposed to the vaginal microbiota (85, 154, 155) that would
colonize the formerly sterile fetus (151, 156). On the other hand, the first neonatal microbiota of
infants born by a cesarean delivery resemble those of human skin (151). Thus, if there were a
placental microbiota, the fetus would likely be colonized with the first microbiota long before
birth, and placental microbiota could potentially influence neonatal outcomes (157-161). For
example, it has been suggested that the first microbiota shapes the newborn’s immune system and
factor into risks for certain diseases such as type 1 diabetes mellitus, allergies and asthma (36, 37,
162-168).
Urinary tract infection is the number one cause of infection in pregnancy
Urinary tract infections are the most common infections in pregnancy, affecting 5% of all
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pregnant women (169). UTIs are common in pregnancy because pregnancy is associated with
ureteral dilatation, urinary stasis, increases in bladder size and vesicoureteral reflux, and a decrease
in bladder tone (170, 171). Compared to patients without a UTI during pregnancy, the occurrence
of a UTI is associated with low birth weight, preterm birth (< 37weeks), maternal hypertension
and preeclampsia, maternal anemia (hematocrit less than 30%), and chorioamnionitis (171, 172).
The risk of occurrence of these complications is higher among patients with pyelonephritis (i.e.
kidney infection). Acute pyelonephritis occurs in 2% of pregnant women and recurs in 33% of
them (171, 173). The bacteria most responsible for UTIs are Escherichia coli, followed by
Staphylococcus saprophyticus, Streptococcus agalactiae, and Klebsiella and Enterococcus species
(171, 174-176). Recent studies, largely based on molecular techniques, are challenging bladder
sterility by suggesting the existence of a bladder microbiota (118-123, 177). In fact, bladder
microbiota are being proposed to play a role in prostate diseases (178), urinary incontinence (179)
and overactive bladder (180).
Statement of Purpose
There is a causal link between intra-amniotic infection and preterm labor, which is the
number one cause of neonatal morbidity and mortality. Urinary tract infections are the most
common infections in pregnancy and can lead to significant maternal and perinatal complications,
including preterm birth, low birth weight, maternal sepsis, disturbance of the immune system and
an increase in inflammation (171, 172, 175, 181-189). The human placenta and bladder were
historically presumed sterile but are currently hypothesized to harbor their own microbiota in
normal healthy pregnancies. It is critical that these matters be resolved. The purpose of my PhD
research was to evaluate the existence of and, if applicable, to then accurately characterize the
placental and bladder microbiota in pregnancy. Study of the perinatal microbiota via molecular
survey techniques is an essential and timely scientific endeavor for understanding microbial
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etiologies of pregnancy complications.
Specific Aims
The three data chapters of my dissertation research focused on understanding and
objectively characterizing the perinatal microbiota in the previously presumed sterile placenta and
maternal bladder:
The first aim was to determine whether the human placenta harbors a microbiota
irrespective of gestational age (i.e. preterm versus term) or the mode of delivery (i.e. vaginal versus
cesarean) at five different levels of the placenta: amnion, amnion-chorion interface, subchorion,
villous tree, and basal plate. Lower gestational ages (less than 34 weeks) experience intra-amniotic
infection more frequently than higher gestational ages (190, 191), and a causal link has been
established between intra-amniotic infection and preterm birth (22-29). Therefore, it is imperative
that, when evaluating the existence of placental microbiota, we consider preterm and term
placentas separately. In addition, the passage of the placenta through the birth canal during
delivery will likely expose the placenta to vaginal microbiota and/or DNA from this microbiota
(136, 151, 192). Therefore, we addressed and controlled for the mode of delivery as well in
evaluating the existence of a placental microbiota in the contexts of preterm and term births. In
addition, cesarean deliveries that occur after labor, compared to cesarean not in labor (prelabor),
can also lead to placental exposure to vaginal microbiota (127, 193-195). Therefore, when
evaluating the existence of a placental microbiota, it is imperative to account for 1) gestational age
at delivery, 2) mode of delivery, and 3) the occurrence of labor.
The second aim of my dissertation research evaluated the inflammatory response of
trophoblasts to bacteria. Microbiota are the microorganisms residing and potentially growing at a
particular site by overcoming host defense mechanisms and utilizing available nutrients (196-198).
It has been suggested that the placenta has a distinct microbiota that resembles that of the oral
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cavity, and which appears to have spread to the placenta hematogenously (via maternal blood
circulation) (17, 158). We posit that this is unlikely because placental trophoblasts are an effective
barrier to placental microbial colonization. The main cell that forms the placenta is the trophoblast.
It is the first cell type that forms the maternal-fetal barrier at the level of the villous tree.
Trophoblasts are exposed to the contents of maternal blood, including nutrients and potentially
microorganisms.

In a normal placenta, without evidence of chorioamnionitis, the in utero

colonization hypothesis suggests the coexistence of bacteria and trophoblasts does not elicit
inflammation. On the other hand, the “sterile womb” hypothesis suggests that such an interaction
will trigger the release of proinflammatory cytokines and chemokines that may attract
inflammatory cells leading to chorioamnionitis. We propose that trophoblasts represent the first
innate immune defense mechanism against microbial colonization and invasion of the placenta.
This is a trophoblast function that has not been extensively studied yet. Using a human trophoblast
cell line, the third chapter of the dissertation focuses on the innate defense abilities of trophoblasts
by measuring the profiles of their released chemokines, proinflammatory cytokines and antiinflammatory cytokines after exposure to potentially pathogenic bacteria (i.e. Escherichia coli)
and bacteria (i.e. Lactobacillus crispatus and Lactobacillus jensenii) that are common in the human
reproductive tract using specific multiplex immunoassays.
The fourth chapter of my dissertation research evaluated the existence of a bladder
microbiota in healthy asymptomatic pregnant women. Urinary tract infection (UTI) is the number
one cause of infection during pregnancy (169). Pregnancy is associated with ureteral dilatation,
urinary stasis, increase in bladder size and vesicoureteral reflux, and a decrease in bladder tone
(170, 171). Each of these characteristics can promote urogenital tract infection and, as a
consequence, approximately 5% of pregnant women experience a urinary tract infection (UTI)
event with significant maternal and perinatal complications (171, 172, 175, 181-189). We studied
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the urinary microbiota in healthy pregnancy using both culture and molecular surveys. In doing
so, we first determined the most efficacious urine volume and sample collection method for
characterizing the urinary microbiota. We then compared the urinary microbiota of clean catch and
catheterized urine samples with those of paired vaginal swabs. This chapter was done in close
association with Jonathan Greenberg from the Department of Biochemistry, Microbiology and
Immunology at Wayne State University. We contributed equally to this work.
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CHAPTER 2: THE PLACENTAL MICROARCHITECTURE MICROBIOTA STUDY
Introduction
Previous studies reporting the existence of a placental microbiota
Svensson et al. (199) successfully cultivated bacteria from cesarean-delivered placental
tissue samples; however, the majority of bacteria recovered from these tissues were typical human
skin commensals. Using microscopy, Stout et al. (15) documented the presence of intracellular
bacteria in the basal plate of 27% of placentas in the absence of histologic chorioamnionitis. More
recently, Aagaard et al. (17) characterized a placental microbiota and microbiome using data
derived from 16S rDNA amplicon and metagenomic sequencing, respectively. They reported a
low abundance bacterial community that was similar in structure to the oral microbiota and
composed of nonpathogenic commensal bacteria from the phyla Proteobacteria, Tenericutes,
Firmicutes, Bacteroidetes and Fusobacteria. Other studies have also shown that bacterial DNA
detected in the human placenta is indicative of commensal oral bacteria (18, 200, 201), suggesting
hematogenous spread of bacteria, or at least bacterial DNA, from the oral cavity to the placenta.
Collado et al. (202) compared the microbiota of placental samples with those of the human
amniotic fluid, colostrum and meconium. They found that the placental microbiota were not
species rich, but were instead comprised primarily of Proteobacteria. This suggested that the
placental microbiota was likely derived from the intestine rather than the oral cavity. GomezArango et al. (203) subsequently found that Prevotella, Streptococcus, and Veillonella were the
main genera detected in the placenta, and suggested that the origin of a placental microbiota thus
appears to be both the oral and intestinal cavities. However, these studies had notable limitations.
The three principal limitations of prior studies concluding the existence of a human
placental microbiota are a lack of 1) demonstrated viability of surveyed bacteria through culture
(20, 204-208), 2) incorporation of sufficient background technical controls to delineate legitimate
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biological signals from potential background DNA contamination (20, 204, 205, 209, 210), and 3)
addressing complications associated with the mode of delivery (cesarean versus vaginal) (20, 204209). Notably, in some of the most recent studies, attempts were made to incorporate technical
controls for background DNA contamination, yet there was a prolonged time lapse between
placental delivery and processing (2 to 24 hours), during which time placentas were stored at
ambient temperatures (207, 211). This is important because the delay in processing could lead to
the growth of any bacteria that had colonized the placenta during the birthing process and also
potentially to the differential growth of rare bacterial types in the placental samples, if they do
indeed exist. Over the past couple of years, studies addressing the above limitations started to
emerge, including our initial placental microbiota study mentioned below (212). Lauder et al. (110)
evaluated six women who had uncomplicated term vaginal deliveries using quantitative PCR
(qPCR) and 16S rRNA gene sequencing and could not distinguish between the bacterial profiles
of biologic samples and background contamination control. Leiby et al. (213) compared 20 term
and 20 spontaneous preterm deliveries to background controls using 16S rRNA gene sequencing
and shotgun metagenomic sequencing and did not detect a distinct placental microbiome. De
Goffau et al. (214) evaluated placentas from pregnancies complicated by preeclampsia,
spontaneous preterm birth, and small for gestational age infants and concluded that a human
placental microbiome does not exist.
Our initial placental microbiota study
We initially performed a cross-sectional study to evaluate the existence of placental
microbiota (212). Samples were obtained from 29 women who underwent cesarean deliveries at
term without labor. We collected a 1.5 cm2 core sample through the placenta (i.e., amnion through
to basal plate). The tissue sample was taken halfway between the umbilical cord insertion point
and the edge of the placental disk, along the line representing the longest distance from the cord
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insertion point to the edge of the disk. We used cultivation to evaluate the presence of a viable
microbiota in the placenta, but 28 of 29 samples did not yield any bacterial cultivars. One placental
sample did yield three cultivars on a single growth plate, however, corresponding 16S rRNA gene
sequences of these cultivars were not identified in 16S rDNA surveys of this placental sample,
indicating that these three cultivars were likely contaminants from the clinical laboratory. 16S
rRNA gene quantitative real-time PCR (qPCR) and sequencing surveys showed that the
abundance, composition, and structure of the bacterial profiles of placental tissue and background
technical controls did not differ—they overlapped. Furthermore, metagenomic surveys indicated
that the bacterial profiles of placental tissues were dominated by aquatic and plant-associated
bacteria, not by human commensals, and thus again likely reflected background contamination
(108, 112). In summary, using cultivation, qPCR, 16S rRNA gene amplicon, and metagenomic
sequencing surveys, we found no evidence for a microbiota in placentas obtained from cesarean
deliveries at term without labor.
Impetus for the current placental microbiota study
Although our initial study evaluating the existence of a placental microbiota, which
included ample controls for background DNA contamination, indicated the absence of a
microbiota in human placentas obtained from cesarean deliveries at term without labor, it did not
exclude the potential role of placental microbial colonization in preterm birth, and it did not address
whether prior studies’ characterizations of a placental microbiota in normal term pregnancy were
potentially products of bacterial contamination of placental tissues during the vaginal delivery
process and/or the process of labor (20, 204-209). Our initial study also did not address placental
microarchitecture (i.e. it did not separately evaluate the existence of a placental microbiota in the
amnion, amnion-chorion interface, subchorion, villous tree, and basal plate).
Therefore, in my second dissertation chapter, the objective was to evaluate the existence
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of a placental microbiota, while addressing each of the limitations of the prior studies. We
simultaneously considered if there was a difference in placental microbiota profiles between
preterm and term pregnancies, given that placental and intra-amniotic infection is a primary cause
of preterm delivery (22-29), and whether the process of labor exposes the human placenta to
microbial colonization (130). We investigated the bacterial profiles of 69 term and preterm,
cesarean and vaginally-delivered, placentas, and separately analyzed the bacterial profiles of the
amnion, amnion-chorion interface, subchorion, villous tree, and basal plate, and compared them
to those of technical controls for background DNA contamination.
Methods
Study design
This was a prospective, cross-sectional, case-control study. The inclusion criteria were: 1)
singleton gestation with cesarean or vaginal delivery preterm or at term; 2) patients with vaginal
deliveries, non-labor (NIL) cesarean deliveries, or cesarean deliveries while being in labor
secondary to obstetrical indications; 3) patients undergoing preterm delivery after an episode of
spontaneous preterm labor with intact membranes or preterm prelabor rupture of membranes, or
secondary to other indications such as preeclampsia or intrauterine growth restriction; and 4)
patients providing written informed consent to participate in the study. The exclusion criteria
were:1) any maternal or fetal condition requiring termination of pregnancy; 2) known major fetal
anomaly or fetal demise; 3) active vaginal bleeding; 4) multifetal pregnancy; 5) serious medical
illness (e.g. renal insufficiency, congestive heart disease, chronic respiratory insufficiency); 6)
severe chronic hypertension (requiring medication); 7) asthma requiring systemic steroids; 8)
condition requiring anti-platelet or non-steroidal anti-inflammatory drugs; 9) active hepatitis; 10)
clinical chorioamnionitis; or 11) antibiotics use within one month of delivery (excluding
intraoperative prophylaxis (e.g. Cefazolin for cesarean deliveries and Penicillin for GBS
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prophylaxis)).
Sample collection
Immediately following a vaginal or a cesarean section delivery, the placenta was placed in
a sterile container with a sealed cover and transported to a nearby biological safety cabinet in the
clinical laboratory. Therein, swabs (FLOQSwabs, COPAN Diagnostics, Murrieta, CA) were
aseptically collected from the amnion, amnion-chorion interface, subchorion, villous tree, and
basal plate of the placenta. These swabs were taken from two different sites on the placental disc,
each site being halfway between the umbilical cord insertion point and the edge of the placental
disc. Core placental tissue samples (i.e. tissue from the amnion through to the basal plate) were
also collected for bacterial culture.
Bacterial culture of placental tissues
Core placental tissues were transported to the Detroit Medical Center University
Laboratories Microbiology Core within anaerobic transport medium surgery packs (Anaerobe
Systems, AS-914; Morgan Hill, CA) and 0.85% sterile saline solution tubes (Thermo Scientific,
R064448; Waltham, MA) for anaerobic and aerobic culture, respectively. The tissues were
processed for culture on the day of collection, as previously prescribed in Theis et al 2019 (212).
Specifically, tissues were homogenized using a Covidien Precision Disposable Tissue Grinder
(3500SA; Minneapolis, MN) and plated via an inoculating loop on three growth media (trypticase
soy agar with 5% sheep blood, chocolate agar, MacConkey’s agar) at 35° C under anaerobic (5%
CO2, 10% H2, 85% N2) and aerobic (8% CO2) atmospheres for four days. A genital mycoplasma
cultivation assay (Mycofast US; Logan, UT) was also conducted for each placental sample (215).
The taxonomies of resultant isolates were characterized using Matrix-assisted laser
desorption/ionization time-of-flight mass spectrometry (MALDI-TOF) within the Detroit Medical
Center University Laboratories Microbiology Core (216).
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DNA extractions of placental swabs
DNA was extracted from placental swabs using QIAGEN DNeasy PowerLyzer PowerSoil
Kits according to manufacturer’s protocol with minor modifications as described in Winters et al
2019 (117). Two types of technical controls for background DNA contamination were included
for the extraction and sequencing processes: 1) Six DNA extraction kits with Copan FLOQSwabs;
2) Six blank DNA extraction kits. Purified DNA was stored at −20° C.
16S rRNA gene sequencing, processing, and statistical analysis
Using 16S rRNA gene PCR (5 µl template DNA) and Illumina MiSeq protocols (217, 218),
amplification and sequencing of the V4 region of the 16S rRNA gene were performed at the
University of Michigan’s Center for Microbial Systems (Ann Arbor, MI) (217). The forward
primer 5’-3’ was 515F: GTGCCAGCMGCCGCGGTAA and the reverse primer 5’-3’ was 806R:
GGACTACHVGGGTWTCTAAT. Using 35 cycles of standard PCR (for PCR conditions, see
Theis et al (212)), 504 out of 690 placental swab samples (73%) yielded a 16S rRNA gene
amplicon library. The 12 technical control samples did not yield usable amplicon libraries at 35
cycles of amplification; they were subsequently amplified for 40 cycles and then sequenced. These
control samples were used only to gauge the extent to which the bacteria identified in control
samples were also identified in the placental swab samples from the different patient treatment
groups.
Mothur software (v1.39.5) was used to assemble paired-read contigs, trim, filter, and align
sequences, identify and remove chimeras, assign sequences to bacterial taxonomies, and to cluster
sequences into operational taxonomic units (OTUs) based on 97% sequence similarity (219). We
additionally used the program DADA2 to cluster sequences into amplicon sequence variants
(ASVs) which can afford greater resolution of bacterial strains among samples (220). The results
using OTU and ASV approaches were similar, so here we present only the results based on ASV
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data. The sequence data from the two samples from each layer of the placenta from each individual
patient were bioinformatically combined prior to alpha and diversity analyses. Furthermore,
samples were only included in analyses if they had at least 500 quality-filtered sequences and
Good’s coverage values exceeding 95%. Alpha diversity of placental swab samples was examined
using Chao1 richness and Simpson (1 - D) indices (221, 222), and assessed using ANOVA
followed by Tukey’s pairwise comparisons, or Kruskal-Wallis followed by Mann-Whitney U tests,
in PAST (v. 3.14). Beta diversity was assessed using the Jaccard similarity index, which measures
similarities in bacterial profile composition between samples, and the Bray-Curtis similarity index,
which measures similarities in bacterial profile structure between samples. Variation in the
bacterial profiles of the placental samples from different patient groups were visualized through
Principal Coordinates Analyses (PCoA). Non-parametric MANOVA (NPMANOVA) analyses
were conducted using either PAST or the Vegan package in R (v. 2.5-4). Similarity percentage
(SIMPER) analyses were conducted to determine the contribution of individual ASVs to observed
variation in placental bacterial profiles among patient groups (PAST software; v. 3.14).
Results
Maternal characteristics
The demographic and clinical characteristics of the patients in this study are summarized
in Table 2-1. This prospective cross-sectional study included 48 term and 21 preterm patients.
Term deliveries included 18 cesarean not in labor (NIL), 9 cesarean in labor, and 21 vaginal
deliveries. Preterm deliveries included 7 cesarean NIL, 8 cesarean in labor, and 6 vaginal
deliveries. None of the patients had clinical chorioamnionitis, as it was one of the exclusion criteria
for the study. Variation in characteristics among patient groups were assessed using ANOVA,
pairwise t-tests, and chi-square tests in SPSS v. 25 (IBM Corporation, Armonk, NY, USA). No
significant differences of age (p = 0.771) or BMI (p = 0.163) were observed among the six different
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groups. There were also no significant differences in gestational age among the three preterm
groups (p > 0.725) or among the three term groups (p = 1.00). Lastly, there were no significant
differences in birth weight among the three preterm groups (p > 0.418) or among the three term
groups (p > 0.942).
Table 2-1: Demographic and clinical characteristics of patients in this study
Group
Term (n=48)

Preterm
Cesarean in
Labor (n=8)

Preterm
Vaginal (n=6)

27

25.14

27.43

26

25.67

5.63
1.33

5.70
1.9

3.29
0.72

5.19
1.96

3.96
1.40

6.38
2.60

Maximum

42
20
35.42
7.66
1.81
19.8
49.8
39.13
0.68
0.16
37.3
40.3
3161.94
566.56
133.54
2225
4660

36
20
40.26
13.52
4.51
24.2
69.9
39.12
1.33
0.44
37
40.7
3217.78
612.39
204.13
2495
4100

31
19
31.51
7.15
1.56
23.4
49.6
39.21
1.16
0.26
37.1
41
2969.29
508.33
110.93
1825
3720

37
20
42.30
22.48
8.50
20.5
85.0
31.87
4.95
1.87
24.6
36.6
1760
1223.18
462.32
610
3550

33
19
31.75
8.54
3.02
21.3
48.1
31.13
5.02
1.77
22.7
35.6
1508.75
706.39
249.75
540
2385

37
20
31.98
12.61
5.15
20.9
55.1
33.22
4.64
1.89
23.9
36
2205
806.00
329.05
630
2910

African
American

12

8

19

6

8

5

SEMb
Minimum
Maximum
Mean
SDa
SEMb
Minimum
Maximum
Mean
SDa

d

GA at
Delivery
(wks)

SEMb
Minimum
Maximum
Mean

Birthweight
(g)

27.22

Preterm (n=21)
Term Vaginal
(n=21)

SDa

BMIc
(kg/m2)

Term
Cesarean in
Labor (n=9)

Preterm
Cesarean NIL
(n=7)

Mean

Age (years)

Term
Cesarean
NIL (n=18)

SDa
SEMb
Minimum

4
1
1
0
0
1
0
0
0
0
1
0
1
1
0
Positive
4
4
6
2
3
GBSe status
Negative
8
2
12
4
3
6
3
3
1
2
Unknown
aStandard Deviation; bStandard Error of the Mean; cBody Mass Index; dGestational Age; eGroup B Streptococcus
Race

White
Asian
Other

0
0
1
2
3
1

Bacterial cultivation results
The results of bacterial culture of placental tissues from the six patient groups are
summarized in Table 2-2 and Figure 2-1. Logistic regression indicated that vaginal delivery, as
compared to cesarean delivery, increased the likelihood of obtaining a positive bacterial culture
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from placental tissues (p = 0.026). None of the term cesarean deliveries yielded even a single
bacterial cultivar. However, all three patient groups of preterm deliveries did yield bacterial
cultivars. Escherichia coli was not cultured from any placentas delivered at term, yet it was
cultured from placentas in each of the three preterm patient groups, supporting its pathogenic role
in preterm deliveries.
Table 2-2: Detailed account of the results of bacterial culture of placental tissues from the different
patient groups
Number
of
patients

Number of
placentas with
positive culture

% of placentas
with positive
culture

Term CS in Labor

18
9

0
0

0%
0%

Term Vaginal

21

8

38.10%

Preterm CS NIL

7

2

28.60%

Preterm CS in Labor

8

1

12.50%

Preterm Vaginal

6

2

33.30%

Group
Term Cesarean NIL

Isolated bacteria

none
none
Pseudomonas sp.,
Corynebacterium sp. (in three
placentas), Enterococcus
faecalis (in two placentas),
Staphyococcus epidermidis (in
three placentas), Haemophilus
influenzae, Peptoniphilus harei,
Staphylococcus warneri,
Streptococcus anginosus,
Ureaplasma urealyticum,
Streptococcus agalactiae
Escherichia coli, Proteus
vulgaris
Escherichia coli
Escherichia coli,
Staphylococcus epidermidis,
Corynebacterium sp.,
Lactobacillus sp., rare
Bacteroides sp., Prevotella sp.,
Ureaplasma urealyticum,
Streptococcus agalactiae,
Tuberculostearicum sp.
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1
2

8

18

9

2

7
5

13

Term
Term CS in Term Vaginal Preterm CS Preterm CS in
Cesarean NIL
Labor
NIL
Labor
Negative Culture

4

Preterm
Vaginal

Positive Culture

Figure 2-1. Summary of the results of bacterial culture of placental tissues from the different
patient groups
DNA sequencing results
Success of generation of an amplicon library at 35 cycles of PCR amplification
At 35 cycles of amplification, 504 / 690 (73%) placental samples, yet none of the
background technical controls, resulted in the successful generation of a 16S rRNA gene amplicon
library. The background technical controls were subsequently amplified for 40 cycles and
sequenced. However, all principal analyses in this study were performed using only the placental
samples that yielded 16S rRNA gene amplicon libraries at 35 cycles. The composition (i.e.
presence/absence of specific bacterial ASVs) of the bacterial profiles of the technical control
samples was used only to gauge the extent to which the bacteria identified in control samples were
also identified in the placentas of the different patient groups (i.e. based on gestational age at
delivery, mode of delivery, and the occurrence of labor).
The binomial effect of success/failure of amplicon library generation at 35 cycles was
assessed using logistic regression. Specifically, the likelihood of library generation from placental
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samples was compared among the six patient groups (term cesarean NIL, term cesarean in labor,
term vaginal, preterm cesarean NIL, preterm cesarean in labor, preterm vaginal), as well as among
the five levels of the placenta sampled (amnion, amnion-chorion interface, subchorion, villous tree
and basal plate). Compared to the cesarean not in labor group, vaginal delivery led to an increased
likelihood in the generation of amplicon libraries (p < 0.0001). The process of labor also led to an
increased likelihood in the generation of amplicon libraries (p = 0.0002). Lastly, the most external
layers of the placenta (i.e. amnion, amnion-chorion interface, and the basal plate) were more likely
to yield amplicon libraries than were the internal layers of the placenta (i.e. subchorion and the
villous tree) (p = 0.001).
Comparison of the bacterial profile composition of placental samples and technical controls
There were four ASVs that were present in the bacterial profiles of at least one-half of the
background technical controls and at an average percent relative abundance of ≥ 2%. These ASVs,
in order of their highest average relative abundance among the control samples (12.6%, 7.7%,
7.2%, and 6.6%, respectively) were taxonomically identified (via BLAST) as Escherichia coli,
Lactobacillus sp., Lactobacillus iners, and Pseudomonas sp. Nine technical controls yielded at
least 500 quality-filtered 16S rRNA gene sequences and had a Good’s coverage greater than 95%.
Comparisons of the composition of the bacterial profiles of the technical controls to those of the
placental samples indicated that the bacterial profiles of the amnion and the basal plate (i.e. the
most external layers of the placenta) consistently differed from those of the technical controls,
while the profiles of the amnion-chorion interface, subchorion, and the villous tree (i.e. the inner
portions of the placenta) generally did not (Table 2-3, 2-4; NPMANOVA with Holm-Bonferroni
sequential corrections applied). The primary exceptions were that the bacterial profiles of the
amnion-chorion interface and the subchorion of placentas from term cesarean NIL deliveries and
term vaginal deliveries also differed from those of technical controls (Table 2-4). These results
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could be due, in part, to low power as a consequence of low sample sizes for some patient groups.
However, to be conservative, for the broad alpha and beta diversity analyses, we restricted our
analyses to data from the amnion and the basal plate. However, for direct comparisons of term
vaginal and term cesarean NIL deliveries, we also considered data from the amnion-chorion
interface and the subchorion.
Table 2-3: Comparison of the bacterial profile composition of preterm placental samples to
controls (N = 9 controls)
Placental Layer
Preterm cesarean Preterm cesarean in Preterm vaginal
NIL
labor
Amnion
N = 6, p = 0.150
N = 8, p = 0.005
N = 6, p = 0.014
Amnion-chorion
N = 3, p = 0.358
N = 7, p = 0.225
N = 6, p = 0.203
interface
Subchorion
N = 3, p = 1.00
N = 4, p = 1.00
N = 3, p = 1.00
Villous tree
N = 3, p = 1.00
N = 5, p = 1.00
N = 4, p = 1.00
Basal plate
N = 4, p = 0.239
N = 8, p = 0.043
N = 6, p = 0.005

Table 2-4: Comparison of the bacterial profile composition of term placental samples to controls
(N = 9 controls)
Placental Layer
Term cesarean
Term cesarean in
Term vaginal
NIL
labor
Amnion
N = 18, p = 0.003 N = 9, p = 0.003
N = 21, p = 0.003
Amnion-chorion
N = 15, p = 0.005 N = 7, p = 0.234
N = 20, p = 0.003
interface
Subchorion
N = 7, p = 0.019
N = 3, p = 0.582
N = 11, p = 0.044
Villous tree
N = 4, p = 1.00
N = 2, p = 1.00
N = 9, p = 0.203
Basal plate
N = 16, p = 0.003 N = 9, p = 0.003
N = 20, p = 0.003
Taxonomy
With the aim of identifying a potential placental microbiota, a valuable direct comparison
is to compare the bacterial profiles of vaginal and cesarean NIL deliveries, controlled for
gestational age at delivery. In preterm cesarean NIL deliveries, there was a single ASV that was
present at an average relative abundance of > 2% (i.e. “prominent”) among amnion, amnionchorion interface, subchorion, villous tree and basal plate samples. This ASV was Escherichia coli
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– it was the same ASV that was the most prominent member of the bacterial profiles of the
background technical controls. This ASV was also prominent among the amnion, amnion-chorion
interface, subchorion, and basal plate samples from term cesarean NIL deliveries. In contrast, this
ASV was not prominent in the bacterial profiles of term vaginal placental samples, and among
preterm vaginal placental samples, it was prominent only in the amnion-chorion interface. There
were no ASVs that were prominent among all five layers of the placenta in the term cesarean NIL
patient group.
There were four ASVs that were prominent among all five placental layers in the preterm
vaginal delivery group. They were identified as Fusobacterium sp., Lactobacillus sp., Prevotella
sp., and Sneathia species. This was in contrast to the term vaginal delivery group, in which there
were two ASVs that were prominent among all five placental layers: Lactobacillus sp. and
Lactobacillus iners.
Alpha diversity
Alpha diversity was characterized using Chao1 and Simpson (1 – D). The richness of the
bacterial profiles of the amnion and basal plate varied among patient groups (ANOVA; amnion: F
= 17.64, p < 0.0001; basal plate: F = 8.79, p < 0.0001). Specifically, Chao1 index values of the
bacterial profiles of amnion samples of preterm vaginal (419 ± 92 SE) and term vaginal (429 ± 29
SE) deliveries were more than double those of preterm cesarean NIL, preterm cesarean IL, term
cesarean NIL, and term cesarean IL amnion samples (Tukey’s pairwise comparisons; p < 0.002).
The same pattern was evident for bacterial profile richness of the basal plate (ANOVA; F = 8.79,
p < 0.001). Although there was variation in bacterial profile richness among amnion and basal
plate samples in the six patient groups, and more specifically between vaginal and cesarean
deliveries, there was not consistent variation in the evenness of these profiles among patient groups
(Simpson index; Kruskal-Wallis; amnion: H = 12.23, p = 0.032, however, with Holm-Bonferroni
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sequential corrections applied, no pairwise comparisons were significant, with p > 0.105; basal
plate: H = 9.73, p = 0.08).
Further comparison of the richness and evenness of the bacterial profiles of the amnionchorion interface and the subchorion of term vaginal and term cesarean NIL placentas revealed
that the richness of the bacterial profiles of the amnion-chorion interface was nearly three times
higher in vaginal (226 ± 28 SE) than cesarean (85 ± 14 SE) deliveries (Chao1 index; MannWhitney; U = 37.5, p = 0.0002). However, this pattern was not evident in the bacterial profiles of
the subchorion (U = 23, p = 0.179). There were no consistent differences in the evenness of the
bacterial profiles of the amnion-chorion interface and the subchorion between term vaginal and
term cesarean NIL placentas (Simpson index; amnion-chorion interface: U = 144, p 0.855;
subchorion: U = 35, p = 0.791).
Beta diversity
Beta diversity in the bacterial profiles of placental samples was characterized using Jaccard
(i.e. composition) and Bray-Curtis (i.e. structure) similarity indices. Overall, patient identity was
the principal influence on the composition (R2 = 0.57, or 57% of the variance explained, p = 0.001)
and structure (R2 = 0.69, p = 0.001) of amnion and basal plate placental bacterial profiles.
Nevertheless, controlled for patient identity, using the strata command within the adonis
(NPMANOVA) function in the vegan package R, mode of delivery, gestational age at delivery,
and the level of the placenta (i.e. amnion or basal plate) also significantly explained variation in
bacterial profile composition (p = 0.001) and structure (p = 0.001).
When comparing the bacterial profiles of the amnion, amnion-chorion interface,
subchorion, and basal plate of term vaginal and term cesarean NIL placentas, individual patient
identity was again the principal influence on profile composition (R2 = 0.34, p = 0.001) and
structure (R2 = 0.46, p = 0.001). However, controlled for patient identity, there were significant
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effects of both mode of delivery (p = 0.001) and the level of the placenta (p = 0.001). Consideration
of the amnion, amnion-chorion interface, subchorion, and basal plate in isolation demonstrated
clear separation of the structure of the bacterial profiles of samples from term cesarean NIL and
term vaginal deliveries (Figure 2-4). In fact, the overall average dissimilarity between term
cesarean and term vaginal placentas was minimally 93.7% (Figure 2-4).
Similarity percentage (SIMPER) analyses revealed that, compared to cesarean deliveries,
the amnion, amnion-chorion interface, subchorion, and basal plate of placentas from vaginal
deliveries were enriched in Lactobacillus iners (Tables 2-5, 2-6, 2-7, 2-8). The amnion,
subchorion, and basal plate of vaginally-delivered placentas were also enriched in a Lactobacillus
bacterium whose 16S rRNA gene was 100% identical to that of L. crispatus (among other
lactobacilli). In contrast, the bacterial profiles of placentas from cesarean deliveries were
consistently enriched in Staphylococcus (100% 16S rRNA gene sequence identity to S. hominis,
among others) and Escherichia coli (Tables 2-5, 2-6, 2-7, 2-8).
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Figure 2-2: Principal coordinates analysis (PCoA) of the structure (Bray-Curtis similarity index)
of the bacterial profiles of the a) amnion, b) amnion-chorion interface, c) subchorion, and d) basal
plate between term cesarean NIL and term vaginal deliveries. Statistical results from
NPMANOVA are presented.
Table 2-5: Similarity percentage (SIMPER) analysis indicating the ASVs responsible for ≥ 2% of
the variation in bacterial profiles of the amnion between term cesarean NIL and term vaginal
deliveries.
ASV

Average
dissimilarity

Contribution
percentage

Mean abundance
in term cesarean
NIL deliveries

Mean abundance
in term vaginal
deliveries

1218 Lactobacillus iners
7.11
7.58
0.4 %
14.3 %
1156 Staphylococcus sp.
5.11
5.46
10.7 %
3.3 %
3051 Serratia sp.
4.74
5.06
9.5 %
< 0. 001%
1219 Lactobacillus sp.
2.97
3.17
1.8 %
4.7 %
2917 Cupriavidus sp.
2.51
2.68
5.0 %
0%
The total overall average dissimilarity between the amnion bacterial profiles in these patient groups was 93.7%.
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Table 2-6: Similarity percentage (SIMPER) analysis indicating the ASVs responsible for ≥ 2% of
the variation in bacterial profiles of the amnion-chorion interface between term cesarean NIL and
term vaginal deliveries.
ASV

Average
dissimilarity

Contribution
percentage

Mean abundance
in term cesarean
NIL deliveries

Mean abundance
in term vaginal
deliveries

1218 Lactobacillus iners
6.62
6.95
0.3 %
13.3 %
3045 Escherichia coli
4.77
5.01
10.3 %
1.4 %
1156 Staphylococcus sp.
3.37
3.54
6.7 %
2.1 %
2271 Sneathia amnii
2.53
2.66
1.3 %
4.2 %
3051 Serratia sp.
1.94
2.03
3.9 %
0%
The total overall average dissimilarity between the amnion-chorion interface bacterial profiles in these patient groups
was 95.2%.

Table 2-7: Similarity percentage (SIMPER) analysis indicating the ASVs responsible for ≥ 2% of
the variation in bacterial profiles of the subchorion between term cesarean NIL and term vaginal
deliveries.
ASV

Average
dissimilarity

Contribution
percentage

Mean abundance
in term cesarean
NIL deliveries

Mean abundance
in term vaginal
deliveries

1218 Lactobacillus iners
9.67
10.05
0.06 %
19.4 %
53 Unclassified bacterium
3.82
3.97
6.5 %
1.9 %
1302 Streptococcus pneumoniae 3.82
3.97
7.6 %
< 0. 01%
1219 Lactobacillus sp.
3.72
3.86
0.09 %
7.5 %
1221 Lactobacillus sp.
3.23
3.36
6.5 %
< 0. 01%
537 Bacteroides fragilis
3.05
3.17
6.1 %
0%
3300 Akkermansia muciniphila
2.58
2.69
5.2 %
0.02 %
3098 Haemophilus sp.
2.48
2.58
5.0 %
0.7 %
3253 Anaeroplasma sp.
2.35
2.45
4.7 %
< 0. 01%
3152 Pseudomonas aeruginosa
2.14
2.14
4.3 %
0.1 %
The total overall average dissimilarity between the subchorion bacterial profiles in these patient groups was 96.2%.

Table 2-8: Similarity percentage (SIMPER) analysis indicating the ASVs responsible for ≥ 2% of
the variation in bacterial profiles of the basal plate between term cesarean NIL and term vaginal
deliveries.
ASV

Average
dissimilarity

Contribution
percentage

Mean abundance
in term cesarean
NIL deliveries

Mean abundance
in term vaginal
deliveries

1218 Lactobacillus iners
7.26
7.62
0.5 %
14.7 %
1219 Lactobacillus sp.
3.58
3.76
2.9 %
5.0 %
1156 Staphylococcus sp.
3.06
3.22
4.3 %
3.8 %
53 Unclassified bacterium
2.44
2.56
4.6 %
0.4 %
3045 Escherichia coli
2.07
2.17
4.3 %
0.7 %
The total overall average dissimilarity between the basal plate bacterial profiles in these patient groups was 95.3%.
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Discussion
Principal findings
The principal findings of this study were: 1) vaginal delivery increased the likelihood of
obtaining positive bacterial cultures from placental tissues; 2) placentas from term cesarean
deliveries did not yield any bacterial cultivars; 3) bacterial cultivars were recovered from preterm
cesarean and preterm vaginal deliveries; 4) vaginal delivery, the process of labor, and sampling
the more external layers of the placenta (i.e. amnion, amnion-chorion interface, and basal plate)
increased the likelihood of placental samples yielding successful 16S rRNA gene sequence
libraries; 5) the composition of the bacterial profiles of the amnion and basal plate were
consistently different from those of background technical controls; 6) in contrast, the composition
of the bacterial profiles of villous tree samples were not different from those of technical controls
in any patient group; 7) amnion, amnion-chorion interface, and basal plate samples from vaginal
deliveries had much higher bacterial profile richness than those from cesarean deliveries; 8) patient
identity was the principal factor shaping the composition and structure of placental bacterial
profiles; 9) however, controlled for patient identity, mode of delivery, the process of labor, and the
level of the placenta sampled influenced placental bacterial profiles; and 10) whereas the bacterial
profiles of vaginally-delivered placentas were enriched in Lactobacillus iners and what was likely
L. crispatus, the profiles of cesarean delivered placentas were consistently enriched in Escherichia
coli and what was likely Staphylococcus hominis.
There is no evidence for the existence of microbiota in term cesarean placentas
Cultivation results showed that none of the term cesarean delivery yielded a cultivar.
These findings are consistent with our initial placental study (212). Live bacteria were found in
placentas that were delivered vaginally or preterm. 16S rRNA gene sequencing showed that the
composition of bacterial profiles of the villous tree was similar to the control group. Our findings
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found that the delivered placentas acquired bacterial signals on the outer layers of the placenta,
supporting that the placenta would acquire its microbial signal during delivery and not in utero.
Preterm delivery and placental microbiota
Preterm placentas had positive cultivars among all three preterm groups: cesarean in labor,
cesarean not in labor and vaginal deliveries. Escherichia coli was cultivated in one placenta of
each of the three preterm groups (3/21), but in none of the term placentas (0/48). In preterm
cesarean NIL deliveries, Escherichia coli ASV was the single ASV that was present at an average
relative abundance of > 2% (i.e. “prominent”) among amnion, amnion-chorion interface,
subchorion, villous tree and basal plate samples. It was the same ASV that was the most prominent
member of the bacterial profiles of the background technical controls. These findings suggest that
either the signal in the placental microbiota is related to background contamination or related to
the presence of bacteria that are associated with preterm birth (Escherichia coli).
Vaginal delivery exposes the placenta to vaginal microbiota
Thirty-eight percent of our term vaginal placentas had positive culture. In addition, our 16S
rRNA gene sequencing data showed that the microbial signal was localized to the outer layers of
the placenta. Furthermore, SIMPER analyses showed that vaginally-delivered placentas were rich
in Lactobacillus species. Our findings support previous studies that vaginal delivery would expose
the newborn and the placenta to vaginal microbiota (136, 151, 192), and that vaginally-delivered
placentas are thus not suitable for evaluating the existence of a placental microbiota.
Drivers of the structure and composition of the bacterial microbiome
Patient identity was the principal factor shaping the composition and structure of placental
bacterial profiles. When we controlled for patient identity, the level of the placenta sampled (outer
versus inner layers), mode of delivery (vaginal versus cesarean), and process of labor (labor versus
not in labor) influenced placental bacterial profiles. This is biologically plausible because, as the
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placenta is delivered, the layers that are most superficial (i.e. exposed) will acquire bacterial DNA
from the mother’s birth canal and potentially skin. It is also known that pregnancy that ends with
cesarean in labor delivery exposes the intra-amniotic environment to vaginal microbiota more so
than pregnancy that ends in cesarean not in labor delivery (127, 193-195).
Strengths and limitations
This is a rigorous study evaluating the existence of a placental microbiota. It entailed the
investigation of 69 placentas that varied in mode of delivery and gestational age at delivery
(vaginal versus cesarean, term versus preterm, and in labor versus not in labor). In addition, this is
the first study to evaluate the existence of microbiota at the microanatomy level by evaluating
samples obtained at 5 placental layers. Furthermore, this is one of the few studies that performed
bacterial cultures and included background technical controls to avoid potential false interpretation
of next-generation sequencing results. Limitations of the study are that the study population was
predominantly African American, with a high risk for preterm labor and infection. Another
limitation is that we did not perform metagenomics (whole genome or shotgun sequencing) which
would have provided additional information related to different bacterial genes in the microbiome
that may be more or less present in placentas among women delivering preterm and at term.
Conclusion
This study did not find evidence for the existence of a human placental microbiota. Labor
characteristics including preterm delivery, vaginal delivery and labor impacted the culture and
sequence-based bacterial profiles of placental samples. This study indicates that the human
placenta is not an in utero conduit for microbial colonization of the fetus, as has been proposed by
others.
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CHAPTER 3: THE TROPHOBLAST PROTECTS AGAINST BACTERIAL
COLONIZATION BY PRODUCING INFLAMMATORY CYTOKINES AND
CHEMOKINES
Introduction
An innate immune system is needed to defend against any invading bacteria that may lead
to serious morbidity and mortality (223). The two main characteristics of innate immune defenses,
as compared to the adaptive immune defenses, are rapid and nonspecific activities (224, 225). An
innate immune response occurs within minutes to hours of exposure to bacteria while an adaptive
immune response depends on specialized lymphocytes with specific and stronger, but slower,
responses (226). The sterility of the fetus and amniotic fluid depends in part on components of the
innate immune system that are present in trophoblasts, neutrophils, macrophages, natural killer
cells (189, 223, 227-236), fetal membranes (237, 238), and the cervical mucus plug (239-241).
The placenta and the gestational sac are exposed to the maternal blood, uterine
endometrium, cervicovaginal environments, and potentially their resident microbiota.

The

placenta plays a dual role of providing nutrition to the growing fetus while also providing a barrier
against infection. Specifically, the placenta and fetal membranes provide anatomical (242),
biochemical (243-245), and antibacterial (237, 238) barriers to fetal and intra-amniotic microbial
colonization.
Existence of a human placental microbiota is still under debate (17, 19, 149, 202, 203,
207, 211-214, 246-252) . However, among the evidence against the likelihood that bacteria
typically reside within the placenta is the observation that trophoblasts exhibit anti-microbial
properties. Human trophoblasts secrete bactericidal compounds such as - and -defensins (227,
253, 254) and express different Toll-like receptors, including TLR-1 through TLR-10 (255-258),
suggesting this cell-lineage is involved in the local innate immune response. Trophoblasts respond
to both pathogen-associated molecular patterns (PAMPs) and to endogenous damage-associated
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molecular patterns (DAMPs, or alarmins) (259-261), which may be critical in preventing placental
colonization by invading microorganisms. In addition, trophoblasts are the first line of defense
against hematogenous-disseminated bacteria when they encounter the placenta. These concepts
suggest that a sterile placental microenvironment (212-214) is maintained during pregnancy, at
least in part, by trophoblast antimicrobial activity, despite the intrauterine environment being
contiguous with microorganism-rich areas such as the cervix and vagina (87, 262-265). The
specific mechanisms by which trophoblasts possibly maintain placental sterility have been scarcely
studied.
High-throughput 16S rRNA gene sequencing studies examining the composition and
structure of the vaginal microbiota in reproductive-aged women have shown that there are at least
five major community state types, or CSTs, of vaginal bacteria (265, 266). Lactobacillus
crispatus, L. iners, L. jensenii, and L. gasseri are among the most frequently detected bacterial
species in the vagina, although the richness and diversity of the vaginal microbiota are dependent
on the studied population (265, 267). The ability of Lactobacillus species to produce lactic acid,
H2O2 and antimicrobial substances make them a prominent bacterial component of the healthy
cervicovaginal ecosystem (268, 269). Different strains of Lactobacillus exhibit competitive
exclusion of pathogenic bacteria through nutrient competition and activation of the host immune
system (270). Lactobacilli produce defensins, a class of cationic and amphipathic proteins with
diverse mechanisms of action against common vaginal commensal and pathogenic bacteria (e.g.
Escherichia coli), as well as viruses including human immunodeficiency virus (HIV), herpes
simplex virus (HSV) and human papillomavirus (HPV) (267, 271-279).
The dynamics of the intrauterine and cervicovaginal microbiota during pregnancy are the
result of complex interactions between microorganisms and the host immune system. The degree
to which trophoblasts participate in the control of potential placental-colonizing microbiota
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requires further study. Furthermore, previous studies have suggested that trophoblasts may respond
differently to different bacteria (280-287). In this chapter, we compare the cytokine patterns
exhibited by Sw.71, immortalized human first trimester trophoblast cells (288), after in vitro
interactions with E. coli (a common urogenital pathogen), L. jensenii (a vaginal commensal), and
L. crispatus (a hypothesized mutualist and sentinel of the human reproductive tract) (289, 290).
Methods
Cell culture
Sw.71 is a human cell line of trophoblasts obtained during the first trimester of pregnancy
that were immortalized by infection with the telomerase reverse transcriptase (hTERT) gene. This
cell line has phenotypic characteristics associated with normal trophoblasts, including the
expression of cytokeratin 7, vimentin, HLA-G and human chorionic gonadotropin (277).
Sw.71 cells were maintained in DMEM/F‐12 supplemented with 10% heat‐inactivated
FBS, 1.0 mmol/L sodium pyruvate, 10 mmol/L HEPES, 0.10 mmol/L MEM non‐essential amino
acids, 100 units/mL penicillin, and 100 units/mL streptomycin at 37°C in 5% CO2. Prior to
experiments, Sw.71 cells were cultured for six hours in DMEM supplemented with Lactalbumin
Hydrolysate Solution (1X) without antibiotics in order to reduce the presence of FBS.
Bacterial strains
Escherichia coli (E. coli, ATCC® 700926), Lactobacillus jensenii (L. Jensenii, ATCC®
33820) and Lactobacillus jensenii (L. Jensenii, ATCC® 25258) were purchased from American
Type Culture Collection (ATCC, Manassas, VA). E. coli was grown in Luria-Bertani broth
(Sigma, Saint Louis, MO) and L. jenseni and L. crispatus were grown in Medium 416: Lactobacilli
MRS Agar/Broth (Sigma, Saint Louis, MO) at 37 °C with shaking at 180 rpm. Overnight cultures
were diluted into fresh medium and grown to the mid-logarithmic phase (OD600 was between 0.5
and 1.0). Bacteria were then harvested by centrifugation at 2,300 x g for 5 min and re-suspended
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in PBS.
Co-incubation
Sw.71 were incubated for six hours in four conditions (n = 6 replicates for each condition):
without bacteria (control) or with 5 x 105 E. coli, L. jensenii or L. crispatus. Sw.71 responded to
bacterial concentrations of 1 x 105 to 1 x 106. This optimal bacteria / trophoblast cell ratio was
derived from an initial evaluation of the response of Sw.71 to serial dilutions of bacteria (range
1x103 - 1 x107), using the same methodology as described below. After cell culture and coincubation with bacteria, conditioned media were collected and stored at -80°C until analysis.
Multiplex for cytokines/chemokines
Conditioned media were analyzed with a human cytokine/chemokine magnetic bead assay
kit (Milliplex MAG, Millipore, MA, USA). The array included Eotaxin, Granulocyte Macrophage
Colony-Stimulating Factor (GMCSF), Granulocyte Colony-Stimulating Factor (GCSF),
Interferon-induced protein-10 (IP10), Macrophage Inhibitory Protein-1 (MIP-1α), Macrophage
Inhibitory Protein-1 (MIP1), Monocyte Chemotactic Protein-1 (MCP-1), INF, INFγ, IL12p40, IL-12p70, TNF-α, TNF-, IL-1, IL-1, IL-2, IL-3, IL-5, IL-6, IL-4, IL-8, IL-10, IL-13,
IL-15, IL-17, and IL-1ra. Plates were analyzed in a MagPix system (Luminex xMAP, Austin, TX,
USA).
Statistical analysis
One-way analysis of variance with post hoc Tukey’s pairwise comparisons was used to
compare cytokine/chemokine concentrations in the culture media from E. coli, L. jensenii, L.
crispatus and control group (without bacteria). Differences with p ≤ 0.05 were considered
statistically significant. All statistical analyses were carried out using SPSS v.20 software (IBM
Corporation, Armonk, NY, USA).
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Results
Sw.71 co-incubated with E. coli, L. jensenii or L. crispatus resulted in differential secretion
of 11 of the 26 assayed cytokines/chemokines (Table 3-1; Figure 3-1). Sw.71 co-incubated with
any of the three bacteria exhibited increased secretion of IL-8 and GMCSF. The other chemokines
exhibited a tendency toward increased concentrations, with the exception of IP-10 (Figure 3-1).
MCP-1 was only increased in the presence of the two Lactobacillus species (Table 3-1).
Table 3-1: Secretion of cytokines by Sw.71 in the presence of bacteria.
Cytokine/
Chemokine

SW.71

SW.71 + E. coli

IL8

2.72 
1.9

5.43 
1.8
420.80
 17.5

MCP-1

4.15 
3.2

3338.11
 520.7

15.22 
17.0
1.07 
0.7
1.31 
1.2
1.31 
1.5
0.78 
0.1
6.22 
0.47
4.55 
0.35
7.69 
2.6

96.30 
79.4
2.89 
2.8
2.53 
2.6
2.44 
1.5
0.80 
0.6
8.14 
0.75
9.64 
1.13
5.67 
0.5

Chemokines

1.99 
2.1

GMCSF

Pro-inflammatory

mean ±
SD

IL-6

Anti-inflammatory

mean ±
SD

IL-10

IFN2
IL12p40
INF

IL-13
IL-1ra
IL-4

SW.71 + L.crispatus

Fold
change

p value

mean ±
SD

Fold
change

p
value

3

0.04

6.26 
3.9

3

0.001

154

<0.001

542.59 
89.8

199

<0.001

804

<0.001

10977.65
 437.3

2650

<0.001

6

0.02

10

<0.001

3

0.01

6

<0.001

-

NS

5

<0.001

-

NS

2

0.05

-

NS

3

<0.001

-

NS

2

0.03

-

NS

3

<0.001

-

NS

-

NS

149.20 
18.2
5.99 
1.7
6.05 
3.1
2.91 
0.22
2.11 
0.8
10.22 
1.8
14.58 
1.5
6.79 
0.4

SW.71 + L. jensenii
mean ±
SD

5.66 
3.5
161.55
 47.6
8384.72
 832.5
112.62
 13.8
2.47 
2.1
3.51 
1.6
3.03 
1.5
2.34 
0.7
8.90 
0.9
14.89 
1.1
4.90 
0.22

Fold
change

p
value

3

0.002

59

<0.001

2020

<0.001

7

<0.001

2

0.02

3

0.003

2

0.01

3

<0.001

-

NS

3

<0.001

-

NS

All bacteria elicited the secretion of IL-6 and IFN2, two pro-inflammatory cytokines;
however, the two Lactobacillus species induced higher levels of each than did Escherichia, relative
to controls. In addition, both Lactobacillus species resulted in increased secretion of IL-12p40 and
IFN (Table 3-1). A general tendency was that, in the presence of either Lactobacillus species,
secretion of pro-inflammatory cytokines by Sw.71 was decreased (Figure 3-1). Sw.71 cells
responded to co-incubation with both Lactobacillus species by secreting increased levels of IL-10
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and IL-1ra. Only L. crispatus induced a significant increase in IL-13, and both Lactobacillus
species led to a decreased secretion of IL-4 (Table 3-1). E. coli did not modify secretion of antiinflammatory cytokines (Table 3-1; Figure 3-1).

Figure 3-1: Matrix showing the fold change in chemokines and cytokines when trophoblasts are
co-incubated with E. coli, L. jensenii or L. crispatus compared to trophoblasts being incubated
alone.
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Discussion
Sw.71 is a well characterized cell lineage that has been accepted as a study model for
human trophoblast biology (288, 291). Studies have shown that Sw.71 secretes an array of
cytokines when stimulated with different bacterial products (292, 293). In this study, major
products secreted by Sw.71 upon contact with E. coli or the two Lactobacillus species were
chemokines, a property of these trophoblast cells that has been previously reported (288, 294).
Among the secreted chemokines were signals for the attraction of polymorphonuclear cells (IL-8,
GCSF), monocytes/macrophages (GCSF, MCP1) and T lymphocytes (IL-12p40), indicating that
trophoblasts can induce local immune cell recruitment upon contact with typical components of
the cervicovaginal microbiota. Presence of phagocytic cells in the intrauterine environment may
result in bacterial elimination and the arrival of adaptive immune cells linked with effector or
regulatory functions such as microbiota modulation (269, 295).
Our study supports previous findings that suggest that different bacteria may trigger distinct
trophoblast responses (280-287). The results support the existence of separate mechanisms of
bacterial recognition by trophoblasts, or the presence of bacterial products leading to alternative
inflammatory/anti-inflammatory responses. Differential recognition of bacteria by trophoblasts
can be accomplished by interaction with either cytoplasmic receptors (NOD2) or membrane
receptors (TLR), as demonstrated by previous work (296). However, activation of these PAMP
receptors results in the induction of inflammatory responses. We demonstrated that Sw.71 cells
reacted to Lactobacillus strains with a combination of increased secretion of chemokines,
increased secretion of anti-inflammatory cytokines, and low secretion of pro-inflammatory signals.
This response involves a mechanism that is not yet well-characterized involving either differential
recognition of bacterial colonizers or unique products secreted by L. crispatus and L. jensenii,
resulting in a balance that favors anti-inflammatory responses, mediated in the trophoblast by IL-
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10, IL-1ra and IL-13. Previous work using HeLa cells showed that a vaginal strain of L. crispatus
can induce NF-ķB activation and yet maintain low levels of several pro-inflammatory cytokines
(297). Another report, using human ectocervical and endocervical cell lines treated with soluble
products produced by L. crispatus induced responses that may result in cervical epithelial barrier
protection, including secretion of IL-10-- the same response we found in our experiments with
trophoblasts, and that can be interpreted as being conducive to immunomodulation (298).
Recent evidence in non-pregnant women suggests that the endometrial cavity may have a
characteristic microbiota with low biomass (117, 299-310). We do not have information about the
intrauterine microbiota during pregnancy, but placental infections may result from
hematogenously disseminated microorganisms, or more commonly, from microorganisms
ascending from the lower genital tract (27, 29, 311, 312). Placental infection can pose a threat to
pregnancy by enabling microbial access to the intra-amniotic space or to the fetus (27, 29, 311313). Ascending pathogenic microorganisms (e.g. E. coli and Group B Streptococcus) will be
antagonized in several ways by the cervicovaginal microbiota (262, 273), cervical innate immune
cells, and other reproductive tract defense mechanisms, with the trophoblasts being the last barrier
against intrauterine microbial colonization and/or infection.
Conclusion
In conclusion, all three bacterial species triggered significant release of chemokines and
inflammatory cytokines, suggesting that a commensal relationship with trophoblasts may not be
feasible. These findings support the sterility of the human placenta and the “sterile womb”
hypothesis. The differential significant secretion of anti-inflammatory cytokines triggered by the
two Lactobacillus species compared to E. coli deserves further future investigation.
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CHAPTER 4: IS THERE A BLADDER MICROBIOTA IN HUMAN PREGNANCY?
(Jonathan Greenberg, a PhD student in the Department of Biochemistry, Microbiology and
Immunology at Wayne state University contributed to this chapter.)
Introduction
Urine and the bladder have traditionally been regarded as sterile based on the dogma that
negative culture results equate with sterility (124, 314). Around 5% of pregnant women have a
UTI event at some point during the pregnancy (169). Indeed, UTIs during pregnancy are the most
common infections in pregnancy and they can lead to significant maternal and perinatal
complications, including preterm birth, low birth weight, maternal sepsis, disturbance of the
immune system and an increase in inflammation (171, 172, 175, 181-189). Bacterial invasion of
the bladder has been considered pathologic and has been diagnosed as asymptomatic bacteriuria,
cystitis, or pyelonephritis (124, 170, 315, 316). Asymptomatic bacteriuria is the presence of
100,000 CFU/ml without any of these symptoms (170, 315, 316). Asymptomatic bacteriuria has
been reported in up to 10 % of pregnancies (174, 317-319), and if left untreated, it leads to
symptomatic urinary tract infections (UTIs), including pyelonephritis, in 30-40 % of the cases
(176). A commonly used definition of urinary tract infection is bacterial growth of more than
10,000 colonies of a single bacterial type per milliliter (CFU/ml) of urine with one of the following
symptoms: hematuria, dysuria frequency, urgency, or suprapubic pressure (315, 316). Infection of
the kidneys and the presence of systemic signs or symptoms such as fever, nausea and vomiting,
chills, or flank pain indicates pyelonephritis (170, 315, 316). A positive urine culture in pregnancy
has traditionally elicited antibiotic treatment and repeat of culture within a few months to confirm
resolution of infection (170). A recent Cochrane review recommended treatment of asymptomatic
bacteriuria to reduce the incidence of pyelonephritis during pregnancy (174). Knowing that
complications occur in 30-40% of pregnant patients with asymptomatic bacteriuria (176), the
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remaining 60% of pregnant patients with asymptomatic bacteriuria and without complications
indicate that host-microbiota interactions in the urinary tract are not always pathologic.
Pregnancy increases the risk of acquiring UTI, probably due to pregnancy-associated
physiologic changes including increase in bladder size, decrease in bladder tone, urinary stasis and
vesicoureteral reflux (170, 171). UTI is associated with significant odds ratios of 1.4 for low birth
weight, 1.3 for preterm birth (< 37weeks), 1.4 for maternal hypertension and preeclampsia, 1.6 for
maternal anemia (hematocrit less than 30%), and 1.4 for chorioamnionitis (171, 172). Two percent
of pregnant women may develop acute infection of the kidney, or pyelonephritis (171, 173). E.
coli, Staphylococcus saprophyticus, Streptococcus agalactiae, and Klebsiella and Enterococcus
species are the most common bacteria responsible for UTIs (171, 174-176).
However, the traditional perception of the bladder and urine as sterile is being reconsidered
(118-123, 177). Given appropriate cultivation conditions, based on atmospheric, metabolic, and
humidity requirements, microbiota can be cultured from urine in healthy patients (320, 321).
Furthermore, capitalizing on contemporary advances in next-generation sequencing technologies,
urinary microbiota have recently been identified and characterized among asymptomatic nonpregnant women (118-123, 177), and, in one study, among pregnant women (124). These studies
have suggested that bacteria reside in the human bladder as commensals, and even potentially as
mutualists (120). For example, a current hypothesis is that microbiota residing within the bladder
and urine of healthy people competitively exclude potential pathogens and that dysbiosis of these
microbiota could lead to an overgrowth of opportunistic pathogens, resulting in UTI and urinary
urge incontinence (320, 322, 323). However, there are two substantive caveats inherent in
characterizing urinary microbiota profiles through culture or next-generation sequencing. First,
urine samples are susceptible to vulvovaginal contamination, so there is risk that characterized
microbes were not actually residing in the bladder or urine. Second, if there are indeed resident
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urinary microbiota, they are present in very low abundances and thus, when characterizing them
through next-generation sequencing, there is risk of amplifying and characterizing background
bacterial DNA contamination from extraction kits and reagents (107-111).
The principal objective of this study was to characterize the bladder and urinary microbiota
during pregnancy – does it exist and, if so, how is it structured? Secondary objectives were to: 1)
assess similarity of culture and next-generation sequencing characterizations of urinary microbiota
profiles; 2) assess the bacterial load of urine sampled from catheter and clean catch collection
methods via qPCR; 3) compare the urinary microbiota profiles of pregnant women obtained
through catheterized and clean catch urine collection approaches; and 4) contrast the microbiota
profiles of the urine of pregnant women obtained through these two collection approaches with
those of the vagina to assess potential vulvovaginal contamination. These objectives were achieved
by collecting paired catheterized urine, clean catch urine, and vaginal swabs from pregnant women
and characterizing their urine microbiota profiles through both culture and next-generation
sequencing surveys.
Methods
Study design
This was a cross-sectional study examining the urinary and vaginal microbiota in 25
women admitted for delivery after 35 weeks gestation between October 2016 and January 2017.
There were two components to the study. The first component evaluated the bacterial load and
microbial profiles of urine from Foley catheter and clean catch collection methods across a range
of urine volumes (1 ml, 1.8 ml, 5.4 ml, 10 ml, and 25 ml). Previous studies evaluating bladder
microbiota utilized different urine volumes (ranging from 1 to 50 ml) (118-123, 177). The first
component of the current study identified an appropriate urine volume (5.4 ml) to study bladder
microbiota. The second component of the study compared the microbial profiles of 5.4 ml of clean
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catch urine (CC) and vaginal swabs (VS) collected on admission, and 5.4 ml of urine collected at
the time of placement of a Foley catheter. The Foley catheter was placed 8.36 ± 1.93 hours after
the clean catch sample was collected.
Participants were recruited from Wayne State University/Detroit Medical Center, Detroit,
USA. Each provided written informed consent for the collection and use of samples for research
purposes under the protocols approved by the institutional review boards of Wayne State
University and the Eunice Kennedy Shriver National Institute of Child Health and Human
Development, National Institutes of Health, Department of Health and Human Services.
Inclusion criteria: 1) delivery after 35 weeks of gestation, and 2) intact membranes at the
time of collection of vaginal swabs and clean catch urine samples. Exclusion criteria: 1) any
maternal or fetal condition that requires termination of pregnancy; 2) known major fetal anomaly
or fetal demise; 3) active vaginal bleeding; 4) serious medical illness (e.g. renal insufficiency,
congestive heart disease, chronic respiratory insufficiency, etc.); 5) asthma requiring systemic
steroids; 6) patient requiring anti-platelet or non-steroidal anti-inflammatory drugs; 7) active
hepatitis; and 8) signs or symptoms of urinary tract infection or other kinds of infection at the time
of sampling. In the first component of the study assessing potential influence of urine sample
volume on the bacterial signal obtained (a repeated measures analysis), no subject had received
antibiotics in the last week. In the second component of the study evaluating differences in Foley
catheter and clean catch collection methods on urinary bacterial signals, no subject had received
antibiotics in the last month.
Clinical definitions:
Urinary tract infection (UTI) is bacterial growth of more than 10,000 colonies of a single
bacterial type per milliliter (CFU/ml) of urine with one of the following symptoms: hematuria,
dysuria frequency, urgency or suprapubic pressure (304, 305). However, because others have
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recommended a much lower threshold of 100 CFU/ml for diagnosing symptomatic UTIs (313),
we applied the latter definition. Asymptomatic bacteriuria (ASB) is the presence of 100,000
CFU/ml without any associated symptoms (101, 304, 305). Pyelonephritis is infection of the
kidneys and the presence of systemic signs or symptoms such as fever, nausea and vomiting, chills
or flank pain (101, 304, 305). No woman in this study had urinary tract infection, asymptomatic
bacteriuria, or pyelonephritis.
Sample collection
On admission, each woman provided a mid-stream clean catch urine specimen (CC). A
speculum exam was performed, and a sample of vaginal fluid was collected from the posterior
vaginal fornix under direct visualization by an obstetrician using a FLOQSwab (Copan
Diagnostics, Murrieta, CA, USA). During labor or prior to a cesarean delivery, a sterile Foley
catheter was inserted, and a second urine specimen was collected. Urine and vaginal swabs were
frozen at -80°C within one hour of collection.
Bacterial culture of urine
A 2 ml aliquot of urine was sent for bacterial culture. Aliquots of urine were delivered to
the University Laboratories Microbiology Core in the Detroit Medical Center, wherein they were
processed and cultured under aerobic and anaerobic conditions that day. A genital mycoplasma
assay (Mycofast US; Logan, UT) was also conducted for each urine sample (324). Incubation for
aerobic, anaerobic and Mycoplasma/Ureaplasma cultures was performed at 35°C. Aerobic plates
were TSA 5% SB (Trypticase Soy Agar w/5% Sheep's Blood), Columbia CNA SB, MacConkey
and MTM II (Modified Thayer Martin). Anaerobic plates used were Brucella OxyPRAS Plus,
KVL/BBE Biplate (Brucella Laked Blood Agar with Kanamycin and Vancomycin/Bacteroides
Bile Esculin Agar) and CDC ANA BLD (CDC Anaerobic Blood Agar). Aerobic cultures were
grown in an incubator with 8% CO2, anaerobic cultures were grown in a plastic anaerobic culture
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chamber in a non-CO2 incubator, and the Mycoplasma/Ureaplasma cultures were grown in an oxic
environment without CO2 supplementation (in a non-CO2 incubator). In each case, one drop of
urine, equivalent to approximately 0.05 ml, was used. Cultures were checked at 24 hours and if
there was no growth, the culture was re-incubated for another 24 hours. If there was no growth at
48 hours, the culture was declared negative. The taxonomies of resultant isolates were
characterized using Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry
(MALDI-TOF) within the University Laboratories Microbiology Core (216).
DNA extractions of urine and vaginal swabs
Genomic DNA was extracted from urine and vaginal swab specimens using QIAGEN
DNeasy PowerLyzer PowerSoil Kits according to the manufacturer’s protocol with the following
modifications: 1) instead of adding 750 μl of PowerBead Solution to each sample, 500 μl of
PowerBead Solution and 200 μl of phenol/chloroform:isoamyl alcohol were added to each sample
and incubated for 10 minutes in the PowerBead Tubes at room temperature, 2) steps adding
Solution C2 and C3 were combined into one step using 100 μl of each solution and 1 μl of RNase
A enzyme, 3) instead of adding 1200 μl of Solution C4, 650 μl of C4 and 650 μl of 100% ethanol
were added, 4) the dry-spin after Solution C5 was extended from 1 minute to 2 minutes, 5) Solution
C6 was heated to 60°C prior to elution of DNA, and 6) 60 μl instead of 100 μl of Solution C6 were
added to the Spin Column and incubated for 5 minutes before final centrifugation. Purified DNA
was stored at -20°C.
Quantitative real-time PCR (qPCR) of the 16S rRNA genes
Bacterial DNA abundance within samples was determined via quantitative real-time PCR
(qPCR) amplification of the V1 – V2 region of the 16S rRNA gene according to a protocol
described by Dickson et al (325) with minor modifications. These modifications included the use
of a degenerative forward primer (27f-CM: 5’-AGA GTT TGA TCM TGG CTC AG-3’) and a
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degenerate probe containing locked nucleic acids (+) (BSR65/17: 5’-56FAM-TAA +YA+C ATG
+CA+A GT+C GA-BHQ1-3’). All qPCR reactions were performed in triplicate (20 μl each), with
each reaction containing 0.6 μM of 27f-CM primer, 0.6 μM of 357R primer (5’-CTG CTG CCT
YCC GTA G-3’), 0.25 μM of BSR65/17 probe, 10.0 μl of 2X TaqMan Environmental Master Mix
2.0 (Life Technologies, Carlsbad, CA), and 4.0 μl purified DNA. Cycling conditions were as
follows: 95°C for 10 min, and 45 cycles of 94°C for 30 s, 50°C for 30 s, and 72°C for 30 s.
Fluorescent readings were taken at the end of each cycle on an ABI 7500 Real-Time PCR System
(Applied Biosystems, Waltham, MA). Raw amplification data were normalized to the ROX
passive reference dye and analyzed with Standard Curve 3.3.0-SR2-build15 (Thermo Fisher
Cloud), using automatic threshold and baseline settings. Quantification cycle (Cq) values, defined
as the average number of cycles required for normalized fluorescence to exponentially increase,
were calculated.
16S rRNA gene sequencing
16S rRNA gene sequencing was completed on an Illumina MiSeq (San Diego, CA) at the
University of Michigan’s Center for Microbial Systems (Ann Arbor, MI). The V4 region of the
16S rRNA gene was amplified using a slightly modified standard PCR approach (95° for 2 min,
followed by 32 cycles of 95° for 30 s, 55° for 30 s, and 72° for 30 s, with a final elongation step at
72° for 10 min). DNA template volumes were 5 μl for urine and blank DNA extraction kits, and 3
μl for vaginal swabs. The sequencing protocol was Kozich and colleagues’ dual indexing
sequencing strategy for the Illumina MiSeq (217, 218)
16S rRNA gene sequence processing
Sequence data were processed using Mothur software (v1.39.5) (219). Specifically, paired
reads were assembled, quality-filtered (no ambiguous base calls, homopolymers ≤ 8 bases long),
and aligned to the SILVA 16S rDNA reference database (release 102; sequences falling outside
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the target alignment space were removed) (326, 327). Sequences in the final dataset had an average
length of 253 bp. We performed a preclustering step (diffs = 2) to reduce potential influence of
sequencing errors and removed chimeras identified by UCHIME (328). For taxonomic
classification, the SILVA reference database (327) was used with a confidence threshold of 80%.
Sequences from an unknown domain, Eukaryota, Chloroplasts, Mitochondria, or Archaea were
removed. Operational taxonomic units (OTUs) were defined using a 3% sequence dissimilarity.
Good’s coverage values for all urine and vaginal samples exceeded 99%.
For Component 1, blank DNA extraction kit controls were sequenced twice and then
bioinformatically pooled. Those with Good’s coverage values exceeding 98% were retained for
analysis. Component 1 alpha diversity was analyzed after subsampling individual libraries to 447
sequences, which corresponds to the least represented background technical control sample. After
subsampling, coverage remained above 95% except for one sample (91%).
For alpha diversity analyses in Component 2, the least represented sample was excluded
(445 sequences) and the remaining samples were subsampled to 2007 sequences, corresponding
to the second least represented sample. After subsampling, Good’s coverage values for
catheterized urine, clean catch urine, and vaginal swabs remained greater than or equal to 98%.
Statistical analyses
Cultivation
The rate of cultivation of bacterial phylotypes (e.g. genera) from urine was compared
between Foley catheter and clean catch collection methods using generalized estimating equation
models assuming a binomial distribution (i.e. detected or non-detected). Only bacterial types
detected in at least 20% of the samples, regardless the method of collection, were tested.
Significance of the odds ratios was assessed via Wald tests, implemented in the geepack package
in R (v 3.4) (doi: 10.18637/jss.v015.i02). The paired difference in the total number of bacterial
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phylotypes detected within the Foley catheter and clean catch urine samples from each woman
was assessed using a Poisson generalized estimating equation model.
16S rRNA gene qPCR
To assess differences in 16S rDNA abundance between each urine volume and collection
method and blank DNA extraction kit controls, differences in quantification cycle (Cq) were
evaluated via Mann-Whitney tests. To assess variation in 16S rDNA abundance among urine
samples of different volume from the same women, variation in Cq values was evaluated via
repeated-measures analysis of variance (ANOVA) followed by Tukey’s tests for pair-wise
comparisons or Friedman’s analysis of variance (ANOVA) followed by Wilcoxon matched pairs
tests. Statistical analyses were performed using PAST software (v3.16) (329).
16S rRNA gene profile alpha and beta diversity
Alpha diversity was assessed using Chao1 as an indicator of richness and Shannon and
Inverse Simpson as indicators of heterogeneity (evenness). Variation in alpha diversity among
urine and background technical control samples was evaluated through t-tests or Mann-Whitney
tests. For comparisons among different urine volumes (Component 1: 1 ml, 1.8 ml, 5.4 ml, 10 ml,
25 ml) or between sample types (Component 2: Foley catheter urine, clean catch urine, vaginal
swabs) variation in alpha diversity was evaluated through repeated measures ANOVA followed
by Tukey’s matched-pairs or their non-parametric equivalents.
To evaluate differences in beta diversity of 16S rRNA gene profiles, Jaccard (i.e.
composition) and Bray-Curtis (i.e. structure) similarity index values were calculated using OTU
percent relative abundance data within samples and were visualized through Principal Coordinates
Analyses (PCoA). Non-parametric MANOVA (NPMANOVA) tests were performed on Jaccard
and Bray-Curtis similarity indices to assess differences between background technical controls and
different urine volumes (Component 1), and variation among catheterized urine, clean catch urine,
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and vaginal samples (Component 2).
Alpha diversity indices were generated in mothur (v1.39.5) and statistically evaluated in
PAST (v3.16). Beta diversity indices and PCoA plots were generated using PAST software
(v3.16). Non-parametric MANOVA (330-332) tests were performed in PAST for Component 1
and R (version 3.4.2) with adonis in the vegan package for Component 2. Heat maps were
generated via the Morpheus online tool (333).
Linear discriminant analysis effect size (LEfSe)
LEfSe (334) was used to evaluate variation in the relative abundances of specific bacterial
types among the samples from the four sample types: blank extraction kits, Foley catheter urine,
clean catch urine and vaginal swab samples. The heightened relative abundance of bacterial types
in Foley catheter urinary samples helped identify potential members of the bladder microbiota.
Results
Component 1: Comparing the microbial burden and 16S rRNA gene profiles of urine samples
processed at different volumes
Clinical characteristics
Eight women were included in Component 1 of the study. The median and interquartile
range for age were 27.5 (25.2-28.2) years, for body mass index were 31.6 (28.5-45.8) kg/m2, for
gestational age were 39.7 (38.8-40.8) weeks, and for neonatal birthweight were 3,392 (3,2563,882) grams. Each woman was African-American.
Quantitative real-time PCR (qPCR) of 16S rRNA gene abundance in urine samples
Quantitative real-time PCR demonstrated that the median cycle of quantification (Cq)
values for each volume of urine were significantly lower than the median Cq values for blank DNA
extraction kit controls, regardless whether the urine was collected via Foley catheter (MannWhitney; U = 0, p < 0.006) or the mid-stream clean catch method (U = 0, p < 0.009). The volume
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of urine processed did have an effect on Cq value for Foley catheter (repeated measures ANOVA;
F = 9.805, p < 0.0001) and clean catch urine (F = 28.01, p < 0.0001). For both urine collection
methods, a urine volume of 5.4 ml was the lowest volume to yield Cq values that did not
significantly differ from 25 ml of urine (Tukey-adjusted comparisons; p > 0.05) (Figure 4-1).
Figure 4-1: qPCR of
the 16S rRNA gene
showed the microbial
burden
of
urine
exceeds that of DNA
contamination
controls.
Y
axis
represents the number
of
cycles
of
quantification with a
higher
number
representing a lower
concentration,
and
vice versa.

16S rRNA gene profiles of urine samples
Alpha Diversity
Alpha diversity evaluates richness and heterogeneity within a bacterial community.
Bacterial profile richness (Chao1 index) and heterogeneity (Shannon and Inverse Simpson indices)
did not differ between any volume of catheterized or clean catch urine and blank DNA extraction
kits, after correction for multiple comparisons were applied. Sample volume did not significantly
impact the richness or heterogeneity of urine samples collected via Foley catheter or clean catch
methods, after corrections for multiple comparisons were applied.
Beta Diversity
The composition (Jaccard index) and structure (Bray Curtis index) of the bacterial profiles
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of all five volumes of Foley catheter and clean catch urine samples differed from those of blank
DNA extraction kit controls (NPMANOVA; p < 0.05) (Figure 4-2). Subject identity (F = 1.7169,
p = 0.0001), not urine sample volume (p > 0.05) principally influenced the composition and
structure of urine bacterial profiles, regardless the method of collection. Results are illustrated in
Figures 4-2 and 4-3.

Figure 4-2: Principal Coordinates Analysis (PCoA) plots using A) Jaccard and B) Bray-Curtis
similarity indices illustrating that the composition and structure of the bacterial profiles of all urine
samples, independent of sample volume or collection method, were distinct from those of DNA
extraction kit controls (NPMANOVA, P < 0.05). Subject identity, here indicated by color, was the
principal driver of urine bacterial profiles.
Figure 4-3: Heatmap
illustrating variation in
the
profiles
of
prominent OTUs (≥1%
average
relative
abundance)
among
urine samples from
subjects, ordered by
urine collection method
and sample volume. The
bacterial profiles of
blank DNA extraction
kits are also presented.
Component 1 Outcome
Given that sample volume did not impact the alpha and beta diversities of urine bacterial
profiles, and that a sample volume of 5.4 ml was the lowest volume of urine to yield Cq values
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that did not differ from those of 25 ml of urine, we elected to use a urine sample volume of 5.4 ml
in Component 2 of the study.
Component 2: Evaluating differences in microbial burden and 16S rRNA gene profiles between
Foley catheter and mid-stream clean catch urine in relation to those of vaginal swabs
Clinical characteristics
Twenty-five women were included in Component 2 of the study. The median and
interquartile range for age were 24 (22-29) years, for body mass index were 27.5 (23.4-30.9) kg/m2,
for gestational age were 39.3 (39-39.7) weeks, and for neonatal birthweight were 3,165 (2,9353,565) grams. Twenty-three women were African-American and two were Caucasian. Seven
(28%) had a history of at least one lifetime UTI, and two (8%) experienced a UTI episode during
this pregnancy, but none had a UTI within 30 days of sampling/delivery.
Bacterial cultivation
Only three bacterial phylotypes were cultured from at least 20% of all urine samples
(Lactobacilllus species, coagulase negative Staphylococcus species, and Ureaplasma
urealyticum). Each was cultured less frequently from urine obtained through a Foley catheter than
through mid-stream clean catch urine (Table 4-1; Figure 4-4). On average, urine collected via
Foley catheter yielded three less bacterial phylotypes than paired urine samples collected through
clean catch (Poisson generalized estimating equations model; p < 0.001).
Table 4-1: Odds ratios of detecting bacterial phylotypes through culture in urine obtained from a
Foley catheter compared to urine collected through the mid-stream clean catch method.
Bacterial phylotype identified by MALDI-TOF
Lactobacilllus species
Coagulase negative Staphylococcus species
Ureaplasma urealyticum

Odds Ratio

p

q

0.11
0.03
0.34

0.000
0.000
0.007

0.000
0.000
0.007
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Figure 4-4: Urine bacterial cultivation results indicating differential recovery of bacterial
phylotypes from catheterized and clean catch urine.
Alpha Diversity
Catheterized urine, clean catch urine, and vaginal swab samples did not vary in richness
(Chao1 index; Friedman’s ANOVA: p > 0.05), but they did vary in heterogeneity based on
Shannon (Chi2 = 7.28, p = 0.027) and Inverse Simpson (Chi2 = 7.44, p = 0.025) indices (Figure 45A). Pairwise comparisons indicated that the bacterial profiles of Foley catheter and clean catch
urine samples were more heterogenous than those of vaginal swabs (Wilcoxon matched pairs with
Bonferroni corrections applied: Foley catheter, Shannon index: W = 266, p = 0.0054, Inverse
Simpson index: W = 257, p = 0.011; clean catch, Shannon index: W = 277, p = 0.0021, Inverse
Simpson index: W = 253, p = 0.015). However, the heterogeneity of catheterized and clean catch
urine bacterial profiles did not differ (p > 0.05).
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Figure 4-5: Jitter and Principal Coordinates Analysis (PCoA) plots illustrating alpha and beta
diversities of Foley catheter urine, clean catch urine, and vaginal swabs collected from the same
women. Subject identity is indicated by the color scheme across the 4 panels.
Beta Diversity
Overall, subject identity was the principal driver of the composition and structure of the
bacterial profiles of Foley catheter urine, clean catch urine, and vaginal swabs (Figure 4-5B; Table
4-2; Table 4-3). However, controlled for subject identity, the composition of the three sample types
differed from one another (Table 4-2). With respect to structure, the bacterial profiles of
catheterized urine differed from those of clean catch urine and vaginal swabs, but the profiles of
clean catch urine did not differ from their paired vaginal swabs (Table 4-3).
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Table 4-2: Statistical analysis of community composition (Jaccard similarity index) for Foley
catheter urine, clean catch urine, and vaginal swabs.
Jaccard NPMANOVA
Foley Catheter v Clean Catch v Vaginal Swab
Subject (n = 25)
Sample Type
Foley Catheter v Clean Catch
Sample Type within subject
Clean Catch v Vaginal Swab
Sample Type within subject
Foley Catheter v Vaginal Swab
Sample Type within subject

R2

F

P

1.02349
0.98388

0.32957
0.02640

0.0019
0.7941

1.0515

0.02144

0.0022

1.1345

0.02309

0.0014

1.1306

0.02301

0.0027

Table 4-3: Statistical analysis of community structure (Bray-Curtis similarity index) for Foley
catheter urine, clean catch urine, and vaginal swabs.
Bray-Curtis NPMANOVA
Foley Catheter v Clean Catch v Vaginal Swab
Subject (n = 25)
Sample Type
Foley Catheter v Clean Catch
Sample Type within subject
Clean Catch v Vaginal Swab
Sample Type within subject
Foley Catheter v Vaginal Swab
Sample Type within subject

F

R2

P

1.55064
0.87084

0.42797
0.02003

0.0002
0.6228

0.88327

0.01807

0.0222

0.92679

0.01894

0.4834

1.9757

0.03953

0.0460

The bacterial profiles of Foley catheter urine, clean catch urine, and vaginal swabs were
dominated by Lactobacillus and Gardnerella (Figure 4-6). BLAST analysis indicated that OTUs
1 and 2 were Lactobacillus iners and Gardnerella vaginalis, respectively. OTUs 3, 5, and 12 were
each identified as multiple species of Lactobacillus. OTU 3 was identified as Lactobacillus
crispatus, acidophilus, and gallinarum, OTU 5 was identified as Lactobacillus jensenii and
fornicalis, and OTU 12 was identified as Lactobacillus gasseri and johnsonii. Consistent with
prior observations (88, 265, 335-338), the urogenital bacterial profiles of pregnant women were
largely comprised of three community state types: 1) probable dominance by Lactobacillus
crispatus; 2) dominance by Lactobacillus iners; or, 3) co-dominance by Lactobacillus iners and
Gardnerella vaginalis. Besides Lactobacillus and Gardnerella, the bacterial profiles of Foley
catheter urine also variably contained a high relative abundance of an unclassified
Mycoplasmataceae, Escherichia, Streptococcus, and Veillonella.
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Figure 4-6: Heatmap illustrating variation in the profiles of prominent OTUs (≥1% average
relative abundance) among paired Foley catheter urine, clean catch urine, and vaginal swab
samples from pregnant subjects.
Linear discriminant analysis effect size (LEfSe (334)) analysis (Figure 4-7) showing
bacterial types with heightened relative abundance (p-value<0.05) in extraction kits, Foley
catheter, clean catch and vaginal samples. The bacterial types in bold font had a p-value < 0.01,
indicating that Ureaplasma and Gram-positive anaerobic cocci are potential members of a urinary
microbiota.

Figure 4-7: LEfSe analysis showing bacterial types with heightened relative abundance (pvalue<0.05) in extraction kits, Foley catheter, clean catch and vaginal samples. The bacterial types
in bold font had a p-value < 0.01.
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Discussion
Principal findings of the study
The principal findings of the study are: (1) Quantitative real-time PCR showed that
bacterial load exceeded technical controls regardless of urine collection method (Foley catheter or
clean catch) or the volume of urine processed; (2) A urine volume of 5.4 ml was the lowest to yield
a similar 16S rRNA gene load and profile as 25 ml of urine; (3) Cultivation showed three bacteria
were detected in at least 20% of all samples (Lactobacilllus species, Staphylococcus species
coagulase negative, and Ureaplasma urealyticum), and all three were detected less frequently
using the FC than the CC method with odds ratios ranging between 0.03 and 0.34; (4) Cultivation
of FC urine yielded an average of three less bacterial phylotypes than did the CC urine; (5)
Molecular sequencing techniques showed that the bacterial composition of CC urine was similar
to that of VS whereas that of FC urine was dissimilar to that of VS; (6) Ureaplasma urealyticum
was recovered in 13/25 foley catheter samples; (7) The main driver behind the composition and
structure of bacterial communities was patient identity. When we controlled for patient identity,
the structure of the bacterial community of clean catch urine and vaginal swab samples were
similar. On the other hand, FC urine samples were significantly different in structure from CC
urine and VS samples; (8) Potential members of a maternal bladder microbiota are Ureaplasma
urealyticum and Gram-positive anaerobic cocci.
Urinary Tract Infections (UTIs) and Pregnancy
Approximately 10% of women report having at least one episode of UTI in the previous
12 months and the lifetime probability of a woman having at least one UTI event is around 60%
(316, 339-341). Among women with culture-confirmed UTI, around 28% had recurrence within
six months (316, 342). The bacterium most responsible for UTIs is Escherichia coli, followed by
Staphylococcus saprophyticus, Streptococcus agalactiae, and Klebsiella and Enterococcus species
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(171, 174-176). During pregnancy, UTI is associated with adverse ouctcomes including low birth
weight, preterm birth (< 37 weeks), maternal hypertension and preeclampsia, maternal anemia
(hematocrit less than 30%), and chorioamnionitis (171, 172).
In pregnancy, asymptomatic bacteriuria is to be detected and treated because of the
potential serious complication including pyelonephritis, which can occur in 30-40 % of the cases
(176). The American college of Obstetricians and Gynecologists (ACOG) and other societies
recommend urine culture as one of the routine tests to be obtained early in pregnancy (343), with
mid-stream clean catch being the most common collection approach. If mid-stream clean catch
urine culture is performed, the detection of Escherichia coli is predictive of bacterial UTI while
the detection of other bacteria such as enterococci and group B streptococci is not predictive (344).
Negative urine dipsticks and urine microscopy are useful to rule out the likelihood of the presence
of a UTI in asymptomatic non-pregnant women (344).
Vulvovaginal contamination of urine samples
Prior culture based studies concluded that clean catch urine samples obtained from female
patients have poor ability to detect UTI because of contamination from the skin and vaginal flora
(345-347). A study of 113 asymptomatic pregnant women showed a high level of contamination
in clean catch samples (345). Baerheim et al (346) found that employing precautions such as
cleaning the perineum or obtaining mid-stream samples led to similar contamination to samples
obtained without any precautions (346). Lifshitz et al (347) evaluated 242 symptomatic female
patients divided into 3 groups 1) no cleaning, 2) perineal cleaning and midstream sampling, and
3) perineal cleaning, midstream sampling and vaginal tampon. Contamination rate in the three
groups was similar - around 30% (347).
From a clinical perspective, our study supports previous studies that indicated a significant
contamination rate of clean catch samples (345-347). On the other hand, the utilization of catheters,
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instead of clean catch, to obtain urine samples is concerning for a potential increase in the
incidence of UTIs (348-350). During cesarean deliveries, two randomized clinical trials showed
an increase in the incidence of UTIs in the indwelling bladder catheterization group compared to
the no catheterization group (348-350). Mid-stream clean catch remains a more convenient
approach for patients and health care staff; however, culture and molecular survey results of clean
catch samples require careful interpretation.
In the context of next-generation sequencing, it is important that : 1) vulvovaginal
contamination be limited during urine sample collection; 2) collected urine specimens be promptly
frozen to mitigate growth and replication of acquired contaminants; 3) a sufficient volume of urine
is collected for effective DNA extraction; and 4) that background technical controls be included
to account for potential DNA contamination.
5.4 ml urine volume yields an effective quantity of DNA for 16S rRNA sequencing
Previous urine microbiota studies have utilized different sample volumes (between 1 and
50 ml) of urine for 16S rRNA analysis (118-123). Component 1 of our study showed that a volume
of 5.4 mls represents an effective volume for molecular survey analysis. A bacterial signal was
obtained from all urine volumes (1, 1.8, 5.4, 10 and 25 ml). Both urine collection methods (Foley
catheter and clean catch) yielded a bacterial signal greater than technical controls through qPCR.
There were statistically significant higher reads (lower Cq values) in the 5.4, 10.0 and 25.0 ml
groups compared to the 1.0 and 1.8 ml groups. There was no statistical significance between 5.4
ml and either 10.0 or 25.0 ml groups. These results show that a 5.4 ml urine volume yields an
appropriate quantity of DNA for 16S rRNA sequencing and bacterial profiling of urine. Clean
catch urine samples consistently showed a higher number of 16S rRNA gene copies than Foley
catheter samples of the same volume, indicating that the biological source of the sample (i.e., clean
catch versus Foley catheter) is more important than the volume of the sample. These data suggest
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that clean catch samples were likely contaminated by vaginal microbiota.
The Beta diversity of bacterial profiles in urine samples was significantly different from
that of controls regardless of collection method or the urine volume processed. While urine
samples primarily exhibited dominance of 2 to 3 OTUs, controls showed a more even spread
between various OTUs, including common laboratory contaminants such as Escherichia,
Streptococcus and Staphylococcus (108, 112).
Our results suggest that a bladder microbiota exists in pregnancy
For Component 2, while individual identity was the primary driver of sample bacterial
profiles, differences were found for both beta diversity indices between the three sample types:
catheterized urine, clean catch urine, and the vagina. Pairwise comparisons showed that the
bacterial profiles of catheterized urine were different than those of both clean catch urine and
vaginal swabs, whereas the bacterial profiles of clean catch urine were different from those of
vaginal swabs only by composition. This suggests that the profiles of clean catch urine are more
similar to those of the vagina because of anatomic proximity and increased likelihood of vaginal
contamination. Nevertheless, through culture, 16S rRNA gene qPCR, and 16S rRNA gene
sequencing of Foley catheter urine, there appears to be a bladder microbiota in pregnancy. This is
consistent with several other studies that have demonstrated microbiota in the bladder of nonpregnant females and males (118-123).
Potential members of maternal bladder microbiota
Our study showed that catheterized urine samples do yield a 16S signal beyond controls
and suggest it may be an appropriate sample method to evaluate any microbial communities that
may exist in the bladder. Also, our results suggest that vaginal microbiota influence or contaminate
clean catch urine to a larger degree than catheter urine, and that while some catheter samples are
still influenced by vaginal microbes, a potentially unique signal may exist.
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LEfSe analyses identified 11 OTUs that were more relatively abundant in Foley catheter
urine than in blank extraction controls, and five of these OTUs were also more relatively abundant
in catheterized urine than in vaginal swab samples suggesting that these five OTUs are
representative of a bladder microbiota. While only Ureaplasma and Corynebacterium were
recovered from cultivation surveys, Finegoldia and Anaerococcus species are Gram-positive
anaerobic cocci recalcitrant to culture, typically requiring long incubation times and complex
growth requirements(351), suggesting a potential reason they were not recovered in culture. Other
groups investigating urine via molecular surveys have also identified Finegoldia and
Anaerococcus species in non-pregnant females, both healthy and with non-UTI urinary disorders
(123, 322, 352).
Finegoldia has been associated with the genitourinary tract, gastrointestinal tract, and the
skin as a commensal but it has also been isolated from and attributed to infections from wounds
and various body sites making it an opportunistic pathogen (353-356). Difficulty in culturing
Finegoldia cultivation has been evident in clinical reports where accurate diagnoses were
dependent on detection via PCR (357-359) despite cultures yielding negative results.
To more confidently assert that the bladder contains microbiota in pregnancy, a suprapubic
approach would provide better insight. We suspect that the gold standard for culture should be
performed to recognize live bacteria compared to cell free DNA from dead bacteria.
Strengths and limitations
This is the first extensive study that attempts to characterize the urinary microbiota in
pregnancy by comparing the bacterial profiles of Foley catheter urine, clean catch urine, and
vaginal swabs in 25 women. In addition, this is the first study that compared different volumes of
urine to determine the most efficacious volume on which to perform DNA extraction for molecular
surveys. Furthermore, this study utilized cultivation and NGS approaches to study the existence
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and viability of microbiota in the bladder. There are two primary limitations of this study. First,
the surest approach for investigating a potential bladder microbiota would be suprapubic aspiration
of urine in concert with tissue sampling of the bladder epithelium. Second, our study population
mainly consists of one ethnic group (African American). This may raise the possibility that other
ethnic groups may have different bladder microbiota.
Conclusion
Urine obtained through a Foley catheter has a markedly higher bacterial load than does
technical controls for background DNA contamination. 16S rRNA gene surveys show that,
although there is a distinct subject-specific signature in the bacterial communities of both urine
and the vagina, and that there is overlap in the bacterial profiles of urine and the vagina, the profiles
of catheterized urine are nevertheless distinct. Specifically, the bacterial profiles of catheterized
urine are enriched in Ureaplasma and various Gram-positive anaerobic cocci compared to clean
catch urine, vaginal swabs, and technical controls.
Take Home Message
Considered a major milestone in current research, characterizing the perinatal microbiome
would help us understand complications and diseases affecting pregnancy. Rigorous low biomass
microbiome research should include cultivation and next-generation sequencing with the
utilization of background technical controls. We challenged the presumed sterility of the placenta
and the maternal bladder.
There is no evidence for the existence of a placental microbiome by cultivation and next
generation sequencing. Placentas are exposed to bacteria during delivery. Labor, vaginal delivery,
and preterm delivery were the main factors that led to the existence of a bacterial DNA signal in
the placenta. The bacterial DNA signal was significantly localized in the outer layers of the
placenta (amnion, amnion-chorion interface and basal plate) compared to the inner layers
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(subchorion and villous tree), which is consistent with the bacterial signal being acquired during
the delivery process.
The coexistence of bacteria and trophoblasts seems unreasonable without there being a
significant release of proinflammatory cytokines and chemokines. Bacteria that may exist in the
vagina (Lactobacillus species, E. coli) or elsewhere in the reproductive tract would seemingly
cause infection if relocated into other organs such as the placenta. Specifically, we showed that
coincubation of Lactobacillus crsipatus, Lactobacillus jensenii and Escherichia coli with Sw.71
trophoblast leads to signficiant release of proinflammatory cytokines and chemokines.
Urinary tract infection is the number one infection of pregnancy leading to significant
complications, including preterm birth. We challenged the presumed sterility of the bladder by
evaluating Foley catheter and clean catch urine samples and vaginal swabs from 25 healthy
pregnant women. There was significant bacterial burden in all samples compared to technical
controls. Using cultivation and next generation sequencing, we were able to detect bacterial
presence in the bladder, with Ureaplasma urealyticm and Gram-positive anaerobic cocci being
potential members of the bladder microbiota.
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Introduction
Preterm birth is the number one cause of neonatal morbidity and mortality. A causal link
has been established between infection and preterm birth. Urinary tract infection is the number one
infection in pregnancy and is also associated with preterm birth. Evaluating the existence of a
placental and maternal bladder microbiome is a major scientific and clinical milestone in perinatal
medicine with direct relevance to our understanding of placental and urinary tract infection and
preterm birth.
Methodology and Results
Chapter 2: This is a prospective case control study. Sixty-nine placentas were collected
aseptically from six groups of women without infection: term cesarean not in labor (n=18), term
cesarean in labor (n=9), term vaginal (n=21), preterm cesarean not in labor (n=7), preterm cesarean
in labor (n=8), preterm vaginal (n=6). Placental tissue samples underwent cultivation. DNA
extraction, 16S rRNA gene qPCR, and 16S rRNA gene sequencing were performed on swabs that
were collected from five placental levels: amnion, amnion-chorion interface, subchorion, villous
tree and basal plate. Results showed a lack of evidence for the existence of placental microbiota.
Chapter 3: The existence of a placental microbiota depends on the coexistence of
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trophoblasts and bacteria. In this study, we evaluated the inflammatory response of trophoblasts to
co-incubation with three bacterial types: Escherichia coli, Lactobacillus crispatus, and
Lactobacillus jensenii. All three bacteria led to significant generation of chemokines and
inflammatory cytokines compared to control group (incubation without bacteria). These findings
support the conclusion of chapter 2 that the existence of a placental microbiota in healthy placentas
is unlikely to be biologically plausible.
Chapter 4: Urinary tract infection is the number one cause of infection in pregnancy and
it is associated with serious adverse outcomes including preterm birth. This is a prospective case
control study of 25 healthy pregnant women > 35 weeks of gestation. We evaluated the existence
of maternal bladder microbiota by performing cultivation, 16S rRNA gene qPCR, and 16S rRNA
gene sequencing on Foley catheter urine, clean catch urine and vaginal swabs. Foley catheter urine
yielded bacterial cultivars, had a bacterial load exceeding that of technical controls, and bacterial
profiles distinct in some elements from those of the vagina. Specifically, Ureaplasma and Grampositive anaerobic cocci were more relatively abundant in the bladder than in the vagina.
Conclusion
Our studies provide evidence for the sterility of the human placenta and the existence of a
distinct maternal bladder microbiota.
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